Hagop Kantarjian

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Neoplasm Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Quintás-Cardama Alfonso; Kantarjian Hagop; Manshouri Taghi; Luthra Rajyalakshmi; Estrov Zeev; Pierce Sherry; Richie Mary Ann; Borthakur Gautam; Konopleva Marina; Cortes Jorge; Verstovsek Srdan
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Armistead Paul M; de Lima Marcos; Pierce Sherry; Qiao Wei; Wang Xuemei; Thall Peter F; Giralt Sergio; Ravandi Farhad; Kantarjian Hagop; Champlin Richard; Estey Elihu
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Hagop Kantarjian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Manshouri Taghi; Luthra Rajyalakshmi; Estrov Zeev; Pierce Sherry; Richie Mary Ann; Borthakur Gautam; Konopleva Marina; Cortes Jorge; Verstovsek Srdan
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5418-24.
2009: Armistead Paul M; de Lima Marcos; Pierce Sherry; Qiao Wei; Wang Xuemei; Thall Peter F; Giralt Sergio; Ravandi Farhad; Kantarjian Hagop; Champlin Richard; Estey Elihu
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(11):1431-8.
2009: Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Bueso-Ramos Carlos; Abruzzo Lynne; Pierce Sherry; Shan Jianqin; Issa Jean-Pierre; Garcia-Manero Guillermo
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Sampat Keeran; Kantarjian Hagop; Borthakur Gautam
Clofarabine: emerging role in leukemias.
Expert opinion on investigational drugs 2009;18(10):1559-64.
2009: Carter B Z; Mak D H; Woessner R; Gross S; Schober W D; Estrov Z; Kantarjian H; Andreeff M
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(10):1755-62.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Nature reviews. Clinical oncology 2009;6(9):535-43.
2009: Kantarjian Hagop; Pasquini Ricardo; Lévy Vincent; Jootar Saengsuree; Holowiecki Jerzy; Hamerschlak Nelson; Hughes Timothy; Bleickardt Eric; Dejardin David; Cortes Jorge; Shah Neil P
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Cancer 2009;115(18):4136-47.
2009: Jain Nitin; Reuben James M; Kantarjian Hagop; Li Changping; Gao Hui; Lee Bang-Ning; Cohen Evan N; Ebarb Theresa; Scheinberg David A; Cortes Jorge
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Cancer 2009;115(17):3924-34.
2009: Quintás-Cardama Alfonso; De Souza Santos Fabio Pires; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Awais Ahmed; Borthakur Gautam; Cortes Jorge
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Mesa Ruben A; Schwager Susan; Radia Deepti; Cheville Andrea; Hussein Kebede; Niblack Joyce; Pardanani Animesh D; Steensma David P; Litzow Mark R; Rivera Candido E; Camoriano John; Verstovsek Srdan; Sloan Jeffrey; Harrison Claire; Kantarjian Hagop; Tefferi Ayalew
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Leukemia research 2009;33(9):1199-203.
2009: Cole Suzanne; Kantarjian Hagop; Ault Patricia; Cortés Jorge E
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
Clinical lymphoma & myeloma 2009;9(4):324-7.
2009: Rytting Michael E; Kantarjian Hagop; Albitar Maher
Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.
American journal of clinical pathology 2009;132(2):182-5; quiz 306.
2009: Steensma David P; Baer Maria R; Slack James L; Buckstein Rena; Godley Lucy A; Garcia-Manero Guillermo; Albitar Maher; Larsen Julie S; Arora Sujata; Cullen Michael T; Kantarjian Hagop
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3842-8.
2009: Alvarado Yesid; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Borthakur Gautam; Burger Jan; Wierda William; Garcia-Manero Guillermo; Shan Jianqin; Cortes Jorge
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Nussenzveig Roberto H; Cortes Jorge; Sever Matjaz; Quintás-Cardama Alfonso; Ault Pat; Manshouri Taghi; Bueso-Ramos Carlos; Prchal Josef T; Kantarjian Hagop; Verstovsek Srdan
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
International journal of hematology 2009;90(1):58-63.
2009: Borthakur Gautam; Lin E; Jain Nitin; Estey Elihu E; Cortes Jorge E; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Pierce Sherry; Kantarjian Hagop
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Jilani Iman; Donahue Amber C; Estey Elihu H; Kantarjian Hagop
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Experimental hematology 2009;37(7):784-90.
2009: Quintás-Cardama Alfonso; Han Xin; Kantarjian Hagop; Cortes Jorge
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Blood 2009;114(2):261-3.
2009: Garg R; Faderl S; Garcia-Manero G; Cortes J; Koller C; Huang X; York S; Pierce S; Brandt M; Beran M; Borthakur G; Kantarjian H; Ravandi F
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(7):1297-302.
2009: Ma Wanlong; Kantarjian Hagop; Bekele Benjamin; Donahue Amber C; Zhang Xi; Zhang Zhong J; O'Brien Susan; Estey Elihu; Estrov Zeev; Cortes Jorge; Keating Michael; Giles Francis; Albitar Maher
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3820-6.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Shan Jianqin; Borthakur Gautam; Thomas Deborah; Kornblau Steven; O'Brien Susan; Cortes Jorge
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Blood 2009;113(25):6315-21.
2009: Kantarjian Hagop; Cortes Jorge; Kim Dong-Wook; Dorlhiac-Llacer Pedro; Pasquini Ricardo; DiPersio John; Müller Martin C; Radich Jerald P; Khoury H Jean; Khoroshko Nina; Bradley-Garelik M Brigid; Zhu Chao; Tallman Martin S
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Blood 2009;113(25):6322-9.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Ravandi Farhad; O'Brien Susan; Thomas Deborah; Vidal-Senmache Gabriela; Wierda William; Kornblau Steven; Cortes Jorge
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer 2009;115(11):2482-90.
2009: De Padua Silva L; de Lima M; Kantarjian H; Faderl S; Kebriaei P; Giralt S; Davisson J; Garcia-Manero G; Champlin R; Issa J-P; Ravandi F
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Bone marrow transplantation 2009;43(11):839-43.
2009: Jain Nitin; Cortes Jorge; Quintás-Cardama Alfonso; Manshouri Taghi; Luthra Raja; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Leukemia research 2009;33(6):837-9.
2009: Silver Richard T; Cortes Jorge; Waltzman Roger; Mone Manisha; Kantarjian Hagop
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Haematologica 2009;94(5):743-4.
2009: Vega-Ruiz Arturo; Faderl Stefan; Estrov Zeev; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
International journal of hematology 2009;89(4):489-96.
2009: Pavlovsky Carolina; Kantarjian Hagop; Cortes Jorge E
First-line therapy for chronic myeloid leukemia: Past, present, and future.
American journal of hematology 2009;84(5):287-93.
2009: Garg Ravin; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Ravandi Farhad; Lovshe Denise; Pierce Sherry; O'Brien Susan
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Cancer 2009;115(10):2147-54.
2009: Jabbour Elias; Giralt Sergio; Kantarjian Hagop; Garcia-Manero Guillermo; Jagasia Madan; Kebriaei Partow; de Padua Leandro; Shpall Elizabeth J; Champlin Richard; de Lima Marcos
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
Cancer 2009;115(9):1899-905.
2009: Kilpivaara Outi; Mukherjee Semanti; Schram Alison M; Wadleigh Martha; Mullally Ann; Ebert Benjamin L; Bass Adam; Marubayashi Sachie; Heguy Adriana; Garcia-Manero Guillermo; Kantarjian Hagop; Offit Kenneth; Stone Richard M; Gilliland D Gary; Klein Robert J; Levine Ross L
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Nature genetics 2009;41(4):455-9.
2009: Verma Dushyant; Fava Carmen; Kantarjian Hagop; Cortes Jorge
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
American journal of hematology 2009;84(4):256-7.
2009: Samanta A K; Chakraborty S N; Wang Y; Kantarjian H; Sun X; Hood J; Perrotti D; Arlinghaus R B
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Oncogene 2009;28(14):1669-81.
2009: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Koller Charles; Burger Jan; Lerner Susan; Kantarjian Hagop; Keating Michael
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1637-43.
2009: Lee Tai-Sung; Ma Wanlong; Zhang Xi; Giles Francis; Kantarjian Hagop; Albitar Maher
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Cancer 2009;115(8):1692-700.
2009: Tam Constantine S; Abruzzo Lynne V; Lin Katherine I; Cortes Jorge; Lynn Alice; Keating Michael J; Thomas Deborah A; Pierce Sherry; Kantarjian Hagop; Verstovsek Srdan
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
Blood 2009;113(18):4171-8.
2009: Lin Katherine I; Tam Constantine S; Keating Michael J; Wierda William G; O'Brien Susan; Lerner Susan; Coombes Kevin R; Schlette Ellen; Ferrajoli Alessandra; Barron Lynn L; Kipps Thomas J; Rassenti Laura; Faderl Stefan; Kantarjian Hagop; Abruzzo Lynne V
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood 2009;113(14):3168-71.
2009: El Kinge Abdul Rahman; Hatoum Hassan A; Mahfouz Rami A; Otrock Zaher K; Jabbour Elias; Kantarjian Hagop; Bazarbachi Ali
Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
Leukemia research 2009;33(4):565-6.
2009: Ravandi Farhad; Estey Eli; Jones Dan; Faderl Stefan; O'Brien Susan; Fiorentino Jackie; Pierce Sherry; Blamble Deborah; Estrov Zeev; Wierda William; Ferrajoli Alessandra; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Yeh Chen-Hsiung; Tseng Richard; Zhang Zhong; Cortes Jorge; O'Brien Susan; Giles Francis; Hannah Alison; Estrov Zeev; Keating Michael; Kantarjian Hagop; Albitar Maher
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Leukemia research 2009;33(2):212-7.
2009: Jilani I; Wei C; Bekele B N; Zhang Z J; Keating M; Wierda W; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S M; Giles F J; Albitar M
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
International journal of laboratory hematology 2009;31(1):97-105.
2009: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Targeted oncology 2009;4(1):3-10.
2009: Tefferi Ayalew; Levine Ross L; Kantarjian Hagop
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(1 Suppl):114-9.
2009: Verstovsek Srdan; Tefferi Ayalew; Kantarjian Hagop; Manshouri Taghi; Luthra Raja; Pardanani Animesh; Quintás-Cardama Alfonso; Ravandi Farhad; Ault Pat; Bueso-Ramos Carlos; Cortes Jorge E
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2009: Verma Dushyant; O'Brien Susan; Thomas Deborah; Faderl Stefan; Koller Charles; Pierce Sherry; Kebriaei Partow; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer 2009;115(1):101-6.
2009: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Yeh Chen-Hsiung; Zhang Zhong J; Verstovsek Srdan; Albitar Maher
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
The Journal of molecular diagnostics : JMD 2009;11(1):49-53.
2009: Jabbour Elias; Cortés Jorge E; Kantarjian Hagop
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S272-9.
2009: Champlin Richard; de Lima Marcos; Kebriaei Partow; Rondon Gabriela; Fisher Tobi; Jabbour Elias; Cortés Jorge E; Kantarjian Hagop; Anderlini Paolo; Alousi Amin; Hosing Chitra; Shpall Elizabeth; Popat Uday; Qazilbash Muzaffar; Andersson Borje; Giralt Sergio
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S261-5.
2009: Freireich Emil J; Kantarjian Hagop; Keating Michael J
Leukemia research, 2008.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S178.
2009: Lee Tai-Sung; Ma Wanlong; Zhang Xi; Kantarjian Hagop; Albitar Maher
Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.
BMC structural biology 2009;9():58.
2009: Ma Wanlong; Kantarjian Hagop; Yeh Chen-Hsiung; Zhang Zhong J; Cortes Jorge; Albitar Maher
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
Acta haematologica 2009;121(1):27-31.
2009: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Jilani Iman; Sheikholeslami Mohammad R; Donahue Amber C; Ravandi Farhad; Estey Elihu; O'Brien Susan; Keating Michael; Giles Francis J; Albitar Maher
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer biomarkers : section A of Disease markers 2009;5(1):51-8.
2008: Mori Shahram; Cortes Jorge; Kantarjian Hagop; Zhang Weiguo; Andreef Michael; Ravandi Farhad
Potential role of sorafenib in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 2008;49(12):2246-55.
2008: Borthakur Gautam; Kantarjian Hagop; Wang Xuemei; Plunkett William K; Gandhi Varsha V; Faderl Stefan; Garcia-Manero Guillermo; Ravandi Farhad; Pierce Sherry; Estey Elihu H
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Jones Dan; Luthra Rajyalakshmi; Cortes Jorge; Thomas Deborah; O'Brien Susan; Bueso-Ramos Carlos; Hai Seema; Ravandi Farhad; de Lima Marcos; Kantarjian Hagop; Jorgensen Jeffrey L
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Blood 2008;112(13):5190-2.
2008: Kantarjian Hagop
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Clinical advances in hematology & oncology : H&O 2008;6(11):797-9.
2008: Wang Michael; Fayad Luis; Cabanillas Fernando; Hagemeister Fredrick; McLaughlin Peter; Rodriguez Maria A; Kwak Larry W; Zhou Yuhong; Kantarjian Hagop; Romaguera Jorge
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Cancer 2008;113(10):2734-41.
2008: Sekeres Mikkael A; Schoonen W Marieke; Kantarjian Hagop; List Alan; Fryzek Jon; Paquette Ronald; Maciejewski Jaroslaw P
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Journal of the National Cancer Institute 2008;100(21):1542-51.
2008: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Wierda William; Faderl Stefan; Garcia-Manero Guillermo; Issa Jean-Pierre; Estey Elihu; Keating Michael; Freireich Emil J
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Cancer 2008;113(7 Suppl):1933-52.
2008: O'Brien Susan; Thomas Deborah A; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
Cancer 2008;113(8):2097-101.
2008: Tsimberidou Apostolia Maria; Estey Elihu; Wen Sijin; Pierce Sherry; Kantarjian Hagop; Albitar Maher; Kurzrock Razelle
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
Cancer 2008;113(7):1605-13.
2008: Yanada Masamitsu; Borthakur Gautam; Garcia-Manero Guillermo; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop; Estey Elihu
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Leukemia research 2008;32(10):1505-9.
2008: Aribi Ahmed; Kantarjian Hagop; Koller Charles; Thomas Deborah; Faderl Stefan; Garcia-Manero Guillermo; Cortes Jorge
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Cancer 2008;113(6):1338-43.
2008: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Bennett John M; List Alan; Fenaux Pierre; Sanz Guillermo; Issa Jean-Pierre; Freireich Emil J; Garcia-Manero Guillermo
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Garcia-Manero G; Stoltz M L; Ward M R; Kantarjian H; Sharma S
A pilot pharmacokinetic study of oral azacitidine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(9):1680-4.
2008: Vega-Ruiz Arturo; O'Brien Susan; Cortes Jorge; Kebriaei Partow; Thomas Deborah; Kantarjian Hagop; Ravandi Farhad
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Leukemia research 2008;32(9):1468-71.
2008: Yanada Masamitsu; Borthakur Gautam; Ravandi Farhad; Bueso-Ramos Carlos; Kantarjian Hagop; Estey Elihu
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
Haematologica 2008;93(8):1263-5.
2008: Garcia-Manero Guillermo; Assouline Sarit; Cortes Jorge; Estrov Zeev; Kantarjian Hagop; Yang Hui; Newsome Willie M; Miller Wilson H; Rousseau Caroline; Kalita Ann; Bonfils Claire; Dubay Marja; Patterson Tracy-Ann; Li Zuomei; Besterman Jeffrey M; Reid Gregory; Laille Eric; Martell Robert E; Minden Mark
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Blood 2008;112(4):981-9.
2008: Tam Constantine S; Kantarjian Hagop; Garcia-Manero Guillermo; Borthakur Gautam; O'Brien Susan; Ravandi Farhad; Shan Jenny; Cortes Jorge
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Tam Constantine S; O'Brien Susan; Wierda William; Kantarjian Hagop; Wen Sijin; Do Kim-Anh; Thomas Deborah A; Cortes Jorge; Lerner Susan; Keating Michael J
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood 2008;112(4):975-80.
2008: Jabbour Elias; El Ahdab Samih; Cortes Jorge; Kantarjian Hagop
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Expert opinion on investigational drugs 2008;17(7):1127-36.
2008: Verma Dushyant; Kantarjian Hagop; Jain Nitin; Cortes Jorge
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
Leukemia & lymphoma 2008;49(7):1399-402.
2008: Jabbour Elias; Kantarjian Hagop; Jones Dan; Breeden Megan; Garcia-Manero Guillermo; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Cortes Jorge
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood 2008;112(1):53-5.
2008: Verstovsek Srdan; Tefferi Ayalew; Cortes Jorge; O'Brien Susan; Garcia-Manero Guillermo; Pardanani Animesh; Akin Cem; Faderl Stefan; Manshouri Taghi; Thomas Deborah; Kantarjian Hagop
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon P A; Cools J; Gilliland D G; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(6):1117-24.
2008: Jabbour Elias; Issa Jean-Pierre; Garcia-Manero Guillermo; Kantarjian Hagop
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Cancer 2008;112(11):2341-51.
2008: Pye Seonaid M; Cortes Jorge; Ault Patricia; Hatfield Alan; Kantarjian Hagop; Pilot Richard; Rosti Gianantonio; Apperley Jane F
The effects of imatinib on pregnancy outcome.
Blood 2008;111(12):5505-8.
2008: Jilani Iman; Kantarjian Hagop; Faraji Homan; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; O'Brien Susan; Giles Francis; Albitar Maher
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Leukemia research 2008;32(6):936-43.
2008: Samudio Ismael; Kurinna Svitlana; Ruvolo Peter; Korchin Borys; Kantarjian Hagop; Beran Miloslav; Dunner Kenneth; Kondo Seiji; Andreeff Michael; Konopleva Marina
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Molecular cancer therapeutics 2008;7(5):1130-9.
2008: Konopleva Marina; Watt Julie; Contractor Rooha; Tsao Twee; Harris David; Estrov Zeev; Bornmann William; Kantarjian Hagop; Viallet Jean; Samudio Ismael; Andreeff Michael
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Cancer research 2008;68(9):3413-20.
2008: Quintás-Cardama A; Tong W; Kantarjian H; Thomas D; Ravandi F; Kornblau S; Manshouri T; Cortes J E; Garcia-Manero G; Verstovsek S
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(5):965-70.
2008: Borthakur Gautam; Ahdab Samih El; Ravandi Farhad; Faderl Stefan; Ferrajoli Alessandra; Newman Beth; Issa Jean-Pierre; Kantarjian Hagop
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Leukemia & lymphoma 2008;49(4):690-5.
2008: Yanada Masamitsu; Garcia-Manero Guillermo; Borthakur Gautam; Ravandi Farhad; Kantarjian Hagop; Estey Elihu
Relapse and death during first remission in acute myeloid leukemia.
Haematologica 2008;93(4):633-4.
2008: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Sun Weimin; Buller Arlene M; Jilani Iman; Schwartz Joyce G; Giles Francis; Albitar Maher
Higher detection rate of JAK2 mutation using plasma.
Blood 2008;111(7):3906-7.
2008: Lee Tai-Sung; Potts Steven J; Kantarjian Hagop; Cortes Jorge; Giles Francis; Albitar Maher
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Cancer 2008;112(8):1744-53.
2008: Jilani Iman; Kantarjian Hagop; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; Giles Francis J; Albitar Maher
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia research 2008;32(4):643-9.
2008: Quintás-Cardama Alfonso; Cortés Jorge E; Kantarjian Hagop
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Clinical lymphoma & myeloma 2008;8 Suppl 3():S82-8.
2008: Jabbour Elias; Cortés Jorge E; Kantarjian Hagop
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Clinical lymphoma & myeloma 2008;8 Suppl 3():S75-81.
2008: Kantarjian Hagop; Cortes Jorge
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S37-42; quiz S43-S44.
2008: Cortes Jorge; Kantarjian Hagop
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S22-S30.
2008: Ma Wanlong; Kantarjian Hagop; O'Brien Susan; Jilani Iman; Zhang Xi; Estrov Zeev; Ferrajoli Alessandra; Keating Michael; Giles Francis; Albitar Maher
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Cancer 2008;112(6):1306-12.
2008: Garzon Ramiro; Volinia Stefano; Liu Chang-Gong; Fernandez-Cymering Cecilia; Palumbo Tiziana; Pichiorri Flavia; Fabbri Muller; Coombes Kevin; Alder Hansjuerg; Nakamura Tatsuya; Flomenberg Neal; Marcucci Guido; Calin George A; Kornblau Steven M; Kantarjian Hagop; Bloomfield Clara D; Andreeff Michael; Croce Carlo M
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
Blood 2008;111(6):3183-9.
2008: Tefferi Ayalew; Kantarjian Hagop
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
American journal of hematology 2008;83(3):175-7.
2008: Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda W G; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(3):538-43.
2008: Verstovsek Srdan; Manshouri Taghi; Quintás-Cardama Alfonso; Harris David; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Priebe Waldemar; Estrov Zeev
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2008: Kantarjian Hagop; O'Brien Susan; Shan Jianqin; Huang Xuelin; Garcia-Manero Guillermo; Faderl Stefan; Ravandi-Kashani Farhad; Verstovsek Srdan; Beth Rios Mary; Cortes Jorge
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2008: Kantarjian Hagop; Schiffer Charles; Jones Dan; Cortes Jorge
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Blood 2008;111(4):1774-80.
2008: le Coutre Philipp; Ottmann Oliver G; Giles Francis; Kim Dong-Wook; Cortes Jorge; Gattermann Norbert; Apperley Jane F; Larson Richard A; Abruzzese Elisabetta; O'Brien Stephen G; Kuliczkowski Kazimierz; Hochhaus Andreas; Mahon Francois-Xavier; Saglio Giuseppe; Gobbi Marco; Kwong Yok-Lam; Baccarani Michele; Hughes Timothy; Martinelli Giovanni; Radich Jerald P; Zheng Ming; Shou Yaping; Kantarjian Hagop
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: O'Brien Susan; Ravandi Farhad; Riehl Todd; Wierda William; Huang Xuelin; Tarrand Jeffrey; O'Neal Brandi; Kantarjian Hagop; Keating Michael
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
Blood 2008;111(4):1816-9.
2008: Jin Linhua; Tabe Yoko; Konoplev Sergej; Xu Yuanyuan; Leysath Clinton E; Lu Hongbo; Kimura Shinya; Ohsaka Akimichi; Rios Mary-Beth; Calvert Leslie; Kantarjian Hagop; Andreeff Michael; Konopleva Marina
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Molecular cancer therapeutics 2008;7(1):48-58.
2007: Borthakur Gautam; Lin E; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Giles Francis; Browning Mary L; Kantarjian Hagop; Keating Michael; O'Brien Susan
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Yanada Masamitsu; Garcia-Manero Guillermo; Borthakur Gautam; Ravandi Farhad; Kantarjian Hagop; Estey Elihu
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
Cancer 2007;110(12):2756-60.
2007: Cortes Jorge; Jabbour Elias; Kantarjian Hagop; Yin C Cameron; Shan Jianqin; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Breeden Megan; Reeves Nubia; Wierda William G; Jones Dan
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Verstovsek Srdan
Treatment of systemic mastocytosis with denileukin diftitox.
American journal of hematology 2007;82(12):1124.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; Kantarjian Hagop
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Cancer journal (Sudbury, Mass.) 2007;13(6):357-65.
2007: Bareng Joanne; Jilani Iman; Gorre Mercedes; Kantarjian Hagop; Giles Francis; Hannah Alison; Albitar Maher
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Leukemia & lymphoma 2007;48(11):2189-95.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Richie Mary Ann; Beran Miloslav; Giles Francis; Verstovsek Srdan
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Cortes Jorge; Quintás-Cardama Alfonso; Garcia-Manero Guillermo; O'Brien Susan; Jones Dan; Faderl Stefan; Ebarb Theresa; Giles Francis; Thomas Deborah; Kantarjian Hagop
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Atallah Ehab; Cortes Jorge; O'Brien Susan; Pierce Sherry; Rios Mary Beth; Estey Elihu; Markman Maurie; Keating Michael; Freireich Emil J; Kantarjian Hagop
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
2007: Koschmieder Steffen; D'Alò Francesco; Radomska Hanna; Schöneich Christine; Chang Ji Suk; Konopleva Marina; Kobayashi Susumu; Levantini Elena; Suh Nanjoo; Di Ruscio Annalisa; Voso Maria Teresa; Watt Julie C; Santhanam Ramasamy; Sargin Bülent; Kantarjian Hagop; Andreeff Michael; Sporn Michael B; Perrotti Danilo; Berdel Wolfgang E; Müller-Tidow Carsten; Serve Hubert; Tenen Daniel G
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.
Blood 2007;110(10):3695-705.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
The New England journal of medicine 2007;357(15):1557; author reply 1557-8.
2007: Tam Constantine S; O'Brien Susan; Lerner Susan; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou Apostolia M; Kantarjian Hagop; Wierda William G
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Leukemia & lymphoma 2007;48(10):1931-9.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Flying under the radar: the new wave of BCR-ABL inhibitors.
Nature reviews. Drug discovery 2007;6(10):834-48.
2007: Deininger Michael W N; Cortes Jorge; Paquette Ron; Park Byung; Hochhaus Andreas; Baccarani Michele; Stone Richard; Fischer Thomas; Kantarjian Hagop; Niederwieser Dietger; Gambacorti-Passerini Carlo; So Charlene; Gathmann Insa; Goldman John M; Smith Douglas; Druker Brian J; Guilhot François
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Cancer 2007;110(7):1509-19.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; O'brien Susan; Borthakur Gautham; Bruzzi John; Munden Reginald; Cortes Jorge
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3908-14.
2007: Kalac Matko; Quintás-Cardama Alfonso; Vrhovac Radovan; Kantarjian Hagop; Verstovsek Srdan
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Cancer 2007;110(5):955-64.
2007: Cortes Jorge; Jabbour Elias; Daley George Q; O'Brien Susan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Zhu Yali; Statkevich Paul; Kantarjian Hagop
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cancer 2007;110(6):1295-302.
2007: Yanada Masamitsu; Huang Xuelin; Garcia-Manero Guillermo; O'brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Issa Jean-Pierre; Kantarjian Hagop; Estey Elihu
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Pan Jingxuan; Quintás-Cardama Alfonso; Manshouri Taghi; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Cancer science 2007;98(8):1223-5.
2007: Atallah Ehab; Durand Jean-Bernard; Kantarjian Hagop; Cortes Jorge
Congestive heart failure is a rare event in patients receiving imatinib therapy.
Blood 2007;110(4):1233-7.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop; Giralt Sergio; Andersson Borje S; Giles Francis; Shpall Elizabeth; Kebriaei Partow; Champlin Richard; de Lima Marcos
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Cancer 2007;110(2):340-4.
2007: Pan J; Quintás-Cardama A; Manshouri T; Giles F J; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1395-404.
2007: Aribi Ahmed; Huh Yang; Keating Michael; O'brien Susan; Ferrajoli Alessandra; Faderl Stefan; Wierda William; Kantarjian Hagop; Ravandi Farhad
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Leukemia research 2007;31(7):939-45.
2007: Beran Miloslav; Wen Sijin; Shen Yu; Onida Francesco; Jelinek Jaroslav; Cortes Jorge; Giles Francis; Kantarjian Hagop
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
Leukemia & lymphoma 2007;48(6):1150-60.
2007: Kantarjian Hagop; Pasquini Ricardo; Hamerschlak Nelson; Rousselot Philippe; Holowiecki Jerzy; Jootar Saengsuree; Robak Tadeusz; Khoroshko Nina; Masszi Tamas; Skotnicki Aleksander; Hellmann Andrzej; Zaritsky Andrey; Golenkov Anatoly; Radich Jerald; Hughes Timothy; Countouriotis Athena; Shah Neil
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Blood 2007;109(12):5143-50.
2007: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Koller Charles; Beran Miloslav; Giles Francis; Ravandi Farhad; Lerner Susan; Kantarjian Hagop; Keating Michael
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Mesa Ruben A; Verstovsek Srdan; Cervantes Francisco; Barosi Giovanni; Reilly John T; Dupriez Brigitte; Levine Ross; Le Bousse-Kerdiles Marie-Caroline; Wadleigh Martha; Campbell Peter J; Silver Richard T; Vannucchi Alessandro M; Deeg H Joachim; Gisslinger Heinz; Thomas Deborah; Odenike Olatoyosi; Solberg Lawrence A; Gotlib Jason; Hexner Elizabeth; Nimer Stephen D; Kantarjian Hagop; Orazi Attilio; Vardiman James W; Thiele Juergen; Tefferi Ayalew;
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Leukemia research 2007;31(6):737-40.
2007: Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Oncology (Williston Park, N.Y.) 2007;21(6):653-62; discussion 663-4, 667-8.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Expert opinion on investigational drugs 2007;16(5):679-87.
2007: Kantarjian Hagop; Giles Francis; List Alan; Lyons Roger; Sekeres Mikkael A; Pierce Sherry; Deuson Robert; Leveque Joseph
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Cancer 2007;109(9):1705-14.
2007: Fenaux Pierre; Raza Azra; Mufti Ghulam J; Aul Carlo; Germing Ulrich; Kantarjian Hagop; Cripe Larry; Kerstens René; De Porre Peter; Kurzrock Razelle
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Blood 2007;109(10):4158-63.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 2007;48(4):802-4.
2007: Soupir Chad P; Vergilio Jo-Anne; Dal Cin Paola; Muzikansky Alona; Kantarjian Hagop; Jones Dan; Hasserjian Robert P
Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
American journal of clinical pathology 2007;127(4):642-50.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Chemaly Roy F; Torres Harrys A; Aguilera Elizabeth A; Mattiuzzi Gloria; Cabanillas Maria; Kantarjian Hagop; Gonzalez Virginia; Safdar Amar; Raad Issam I
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(7):964-7.
2007: Jabbour Elias; O'Brien Susan; Kantarjian Hagop; Garcia-Manero Guillermo; Ferrajoli Alessandra; Ravandi Farhad; Cabanillas Maria; Thomas Deborah A
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood 2007;109(8):3214-8.
2007: Atallah Ehab; Kantarjian Hagop; Cortes Jorge
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S105-12.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Rios Mary Beth; Giles Francis; Kantarjian Hagop
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S51-7.
2007: Boumber Yanis A; Kondo Yutaka; Chen Xuqi; Shen Lanlan; Gharibyan Vazganush; Konishi Kazuo; Estey Elihu; Kantarjian Hagop; Garcia-Manero Guillermo; Issa Jean-Pierre J
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
Cancer research 2007;67(5):1997-2005.
2007: Konoplev Sergej; Rassidakis Georgios Z; Estey Elihu; Kantarjian Hagop; Liakou Chrysoula I; Huang Xuelin; Xiao Lianchun; Andreeff Michael; Konopleva Marina; Medeiros L Jeffrey
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
Cancer 2007;109(6):1152-6.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge
Clinical activity of tipifarnib in hematologic malignancies.
Expert opinion on investigational drugs 2007;16(3):381-92.
2007: Heidel Florian; Cortes Jorge; Rücker Frank G; Aulitzky Walter; Letvak Laurie; Kindler Thomas; Huber Christoph; Döhner Hartmut; Kantarjian Hagop; Fischer Thomas
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Cancer 2007;109(5):907-14.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Giles Francis; Thomas Deborah; Wierda William; Cortes Jorge
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Ma Wanlong; Tseng Richard; Gorre Mercedes; Jilani Iman; Keating Michael; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Giles Francis; Albitar Maher
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Haematologica 2007;92(2):170-5.
2007: Jeha Sima; Kantarjian Hagop
Clofarabine for the treatment of acute lymphoblastic leukemia.
Expert review of anticancer therapy 2007;7(2):113-8.
2007: Corey Seth J; Minden Mark D; Barber Dwayne L; Kantarjian Hagop; Wang Jean C Y; Schimmer Aaron D
Myelodysplastic syndromes: the complexity of stem-cell diseases.
Nature reviews. Cancer 2007;7(2):118-29.
2007: Giles Francis J; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Thomas Deborah; Wierda William; Ferrajoli Alessandra; Kornblau Steven; Pierce Sherry; Albitar Maher; Cortes Jorge; Kantarjian Hagop
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Aribi Ahmed; Borthakur Gautam; Ravandi Farhad; Shan Jianqin; Davisson Jan; Cortes Jorge; Kantarjian Hagop
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Cancer 2007;109(4):713-7.
2007: Estey Elihu; de Lima Marcos; Tibes Raoul; Pierce Sherry; Kantarjian Hagop; Champlin Richard; Giralt Sergio
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Blood 2007;109(4):1395-400.
2007: Albitar Maher; Vose Julie M; Johnson Marcella M; Do Kim-Ann; Day Amanda; Jilani Iman; Kantarjian Hagop; Keating Michael; O'Brien Susan M; Verstovsek Srdan; Armitage James O; Giles Francis J
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Leukemia research 2007;31(2):139-45.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Giles Francis; Kantarjian Hagop
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Seminars in hematology 2007;44(1 Suppl 1):S25-31.
2007: Alvarez Ricardo H; Kantarjian Hagop; Cortes Jorge E
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Seminars in hematology 2007;44(1 Suppl 1):S4-14.
2007: Jabbour Elias; Kantarjian Hagop
Introduction: chronic myelogenous leukemia (CML).
Seminars in hematology 2007;44(1 Suppl 1):S1-3.
2007: Atallah Ehab; Kantarjian Hagop; Cortes Jorge
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Nature medicine 2007;13(1):14; author reply 15-6.
2007: Atallah Ehab; Kantarjian Hagop; Garcia-Manero Guillermo
The role of decitabine in the treatment of myelodysplastic syndromes.
Expert opinion on pharmacotherapy 2007;8(1):65-73.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Estrov Zeev; Giles Francis; Murgo Anthony; Ladie Nakia; Verstovsek Srdan; Cortes Jorge
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Giles Francis; Rizzieri David; Karp Judith; Vey Norbert; Ravandi Farhad; Faderl Stefan; Khan Khuda Dad; Verhoef Gregor; Wijermans Pierre; Advani Anjali; Roboz Gail; Kantarjian Hagop; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon M G J; Karsten Verena; Cahill Ann; Albitar Maher; Mufti Ghulam; O'Brien Susan
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Giles Francis J; Cortes Jorge; Jones Dan; Bergstrom Donald; Kantarjian Hagop; Freedman Steven J
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Blood 2007;109(2):500-2.
2007: Quintas-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Nicaise Claude; O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2007: Kantarjian Hagop; Oki Yasuhiro; Garcia-Manero Guillermo; Huang Xuelin; O'Brien Susan; Cortes Jorge; Faderl Stefan; Bueso-Ramos Carlos; Ravandi Farhad; Estrov Zeev; Ferrajoli Alessandra; Wierda William; Shan Jianqin; Davis Jan; Giles Francis; Saba Hussain I; Issa Jean-Pierre J
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2006: Ahmed Bilal; Estey Elihu; Manning John; David Cynthia; Keating Michael J; Kantarjian Hagop; Tsimberidou Apostolia-Maria
Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
Haematologica 2006;91(12 Suppl):ECR55.
2006: Quintás-Cardama Alfonso; Kantarjian Hagop; Cortes Jorge
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Future oncology (London, England) 2006;2(6):655-65.
2006: Verstovsek Srdan; Quintás-Cardama Alfonso; Kantarjian Hagop; Tefferi Ayalew
Experimental therapy in myelofibrosis with myeloid metaplasia.
Expert opinion on investigational drugs 2006;15(12):1555-63.
2006: Verstovsek Srdan; Giles Francis; Quintás-Cardama Alfonso; Perez Nichole; Ravandi-Kashani Farhad; Beran Miloslav; Freireich Emil; Kantarjian Hagop
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Hematological oncology 2006;24(4):181-8.
2006: Verstovsek Srdan; Giles Francis J; Quintás-Cardama Alfonso; Manshouri Taghi; Huynh Ly; Manley Paul; Cortes Jorge; Tefferi Ayalew; Kantarjian Hagop
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Giles Francis; Verstovsek Srdan; Faderl Stefan; Vey Norbert; Karp Judy; Roboz Gail; Khan Khuda Dan; Cooper Maureen; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon; Karsten Verena; Cahill Ann; Albitar Maher; Kantarjian Hagop; O'Brien Susan; Feldman Eric
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Tsimberidou Apostolia-Maria; Kantarjian Hagop; Keating Michael J; Estey Elihu
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Leukemia & lymphoma 2006;47(11):2282-8.
2006: Jabbour Elias; Cortes Jorge; Kantarjian Hagop
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Current opinion in oncology 2006;18(6):578-83.
2006: Ma W; Kantarjian H; Jilani I; Gorre M; Bhalla K; Ottmann O; Giles F; Albitar M
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):1989-91.
2006: Levis Mark; Brown Patrick; Smith B Douglas; Stine Adam; Pham Rosalyn; Stone Richard; Deangelo Daniel; Galinsky Ilene; Giles Frank; Estey Elihu; Kantarjian Hagop; Cohen Pamela; Wang Yanfeng; Roesel Johannes; Karp Judith E; Small Donald
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
2006: Verstovsek Srdan; Akin Cem; Manshouri Taghi; Quintás-Cardama Alfonso; Huynh Ly; Manley Paul; Tefferi Ayalew; Cortes Jorge; Giles Francis J; Kantarjian Hagop
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Jilani I; Keating M; Day A; William W; Kantarjian H; O'brien S; Giles F J; Albitar M
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies.
Clinical and laboratory haematology 2006;28(5):325-31.
2006: Thomas Deborah A; Ravandi Farhad; Kantarjian Hagop
Monoclonal antibody therapy for hairy cell leukemia.
Hematology/oncology clinics of North America 2006;20(5):1125-36.
2006: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Jabbour Elias; Giles Francis; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Shan Jenny; Verstovsek Srdan; Cortes Jorge
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Quintas-Cardama Alfonso; Aribi Ahmed; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Verstovsek Srdan
Novel approaches in the treatment of systemic mastocytosis.
Cancer 2006;107(7):1429-39.
2006: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios M B; Verstovsek S; Cortes J
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1767-73.
2006: Kovitz Craig; Kantarjian Hagop; Garcia-Manero Guillermo; Abruzzo Lynne V; Cortes Jorge
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Blood 2006;108(8):2811-3.
2006: Kantarjian Hagop; Jabbour Elias; Grimley Joanne; Kirkpatrick Peter
Dasatinib.
Nature reviews. Drug discovery 2006;5(9):717-8.
2006: Arana-Yi Cecilia; Quintás-Cardama Alfonso; Giles Francis; Thomas Deborah; Carrasco-Yalan Antonio; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Chen Weina; Rassidakis Georgios Z; Li Jiang; Routbort Mark; Jones Daniel; Kantarjian Hagop; Medeiros L Jeffrey; Bueso-Ramos Carlos E
High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei).
Blood 2006;108(5):1783-4.
2006: Orsolic Nada; Golemovic Mirna; Quintás-Cardama Alfonso; Scappini Barbara; Manshouri Taghi; Chandra Joya; Basic Ivan; Giles Francis; Kantarjian Hagop; Verstovsek Srdan
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Cancer science 2006;97(9):952-60.
2006: Baccarani Michele; Saglio Giuseppe; Goldman John; Hochhaus Andreas; Simonsson Bengt; Appelbaum Frederick; Apperley Jane; Cervantes Francisco; Cortes Jorge; Deininger Michael; Gratwohl Alois; Guilhot François; Horowitz Mary; Hughes Timothy; Kantarjian Hagop; Larson Richard; Niederwieser Dietger; Silver Richard; Hehlmann Rudiger;
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2006;108(6):1809-20.
2006: Tefferi Ayalew; Barosi Giovanni; Mesa Ruben A; Cervantes Francisco; Deeg H Joachim; Reilly John T; Verstovsek Srdan; Dupriez Brigitte; Silver Richard T; Odenike Olatoyosi; Cortes Jorge; Wadleigh Martha; Solberg Lawrence A; Camoriano John K; Gisslinger Heinz; Noel Pierre; Thiele Juergen; Vardiman James W; Hoffman Ronald; Cross Nicholas C P; Gilliland D Gary; Kantarjian Hagop;
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Giles Francis; Fischer Thomas; Cortes Jorge; Garcia-Manero Guillermo; Beck Joachim; Ravandi Farhad; Masson Eric; Rae Patricia; Laird Glen; Sharma Sunil; Kantarjian Hagop; Dugan Margaret; Albitar Maher; Bhalla Kapil
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
British journal of haematology 2006;134(3):341-3.
2006: Samanta Ajoy K; Lin Hui; Sun Tong; Kantarjian Hagop; Arlinghaus Ralph B
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Cancer research 2006;66(13):6468-72.
2006: Giles Francis; Verstovsek Srdan; Garcia-Manero Guillermo; Thomas Deborah; Ravandi Farhad; Wierda William; Ferrajoli Alessandra; Kornblau Steve; Jabbour Elias; Shan Jianqin; O'brien Susan; Albitar Maher; Kantarjian Hagop
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Tsimberidou Apostolia M; Catovsky Daniel; Schlette Ellen; O'Brien Susan; Wierda William G; Kantarjian Hagop; Garcia-Manero Guillermo; Wen Sijin; Do Kim-Anh; Lerner Susan; Keating Michael J
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Cancer 2006;107(1):125-35.
2006: Cheson Bruce D; Greenberg Peter L; Bennett John M; Lowenberg Bob; Wijermans Pierre W; Nimer Stephen D; Pinto Antonio; Beran Miloslav; de Witte Theo M; Stone Richard M; Mittelman Moshe; Sanz Guillermo F; Gore Steven D; Schiffer Charles A; Kantarjian Hagop
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Blood 2006;108(2):419-25.
2006: Tsimberidou Apostolia-Maria; Tirado-Gomez Maribel; Andreeff Michael; O'Brien Susan; Kantarjian Hagop; Keating Michael; Lopez-Berestein Gabriel; Estey Elihu
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Leukemia & lymphoma 2006;47(6):1062-8.
2006: Kantarjian Hagop; Giles Francis; Wunderle Lydia; Bhalla Kapil; O'Brien Susan; Wassmann Barbara; Tanaka Chiaki; Manley Paul; Rae Patricia; Mietlowski William; Bochinski Kathy; Hochhaus Andreas; Griffin James D; Hoelzer Dieter; Albitar Maher; Dugan Margaret; Cortes Jorge; Alland Leila; Ottmann Oliver G
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Talpaz Moshe; Shah Neil P; Kantarjian Hagop; Donato Nicholas; Nicoll John; Paquette Ron; Cortes Jorge; O'Brien Susan; Nicaise Claude; Bleickardt Eric; Blackwood-Chirchir M Anne; Iyer Vishwanath; Chen Tai-Tsang; Huang Fei; Decillis Arthur P; Sawyers Charles L
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Ma W; Jilani I; Gorre M; Keating M; Chan H; Tseng R; Kantarjian H; O'Brien S; Giles F J; Albitar M
Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia.
British journal of haematology 2006;133(6):690-2.
2006: Razzouk Bassem I; Estey Elihu; Pounds Stanley; Lensing Shelly; Pierce Sherry; Brandt Mark; Rubnitz Jeffrey E; Ribeiro Raul C; Rytting Michael; Pui Ching-Hon; Kantarjian Hagop; Jeha Sima
Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.
Cancer 2006;106(11):2495-502.
2006: Hock Barry D; McKenzie Judith L; Patton Nigel W; Drayson Mark; Taylor Karen; Wakeman Chris; Kantarjian Hagop; Giles Francis; Albitar Maher
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Cancer 2006;106(10):2148-57.
2006: Estey Elihu; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Verstovsek Srdan; Jones Dan; Kantarjian Hagop
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood 2006;107(9):3469-73.
2006: Kantarjian Hagop; Issa Jean-Pierre J; Rosenfeld Craig S; Bennett John M; Albitar Maher; DiPersio John; Klimek Virginia; Slack James; de Castro Carlos; Ravandi Farhad; Helmer Richard; Shen Lanlan; Nimer Stephen D; Leavitt Richard; Raza Azra; Saba Hussain
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Cancer 2006;106(8):1794-803.
2006: Yin C Cameron; Cortes Jorge; Barkoh Bedia; Hayes Kimberly; Kantarjian Hagop; Jones Dan
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Cancer 2006;106(8):1730-8.
2006: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Keating Michael; Thomas Deborah; Clarke Charlotte; Jilani Iman; Aguilar Christine; Estey Elihu; Kantarjian Hagop
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
Cancer 2006;106(7):1587-94.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Beran Miloslav; Shen Yu; Onida Francesco; Wen Sijin; Kantarjian Hagop; Estey Elihu
Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Leukemia & lymphoma 2006;47(3):417-23.
2006: Patel Sandip P; Garcia-Manero Guillermo; Ferrajoli Alexandra; Faderl Stefan; Verstovek Serge; Kantarjian Hagop; Estey Elihu
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Leukemia research 2006;30(3):362-3.
2006: Wierda William; O'brien Susan; Faderl Stefan; Ferrajoli Alessandra; Wang Xuemei; Do Kim-Anh; Garcia-Manero Guillermo; Thomas Deborah; Cortes Jorge; Ravandi-Kashani Farhad; Giles Francis; Lerner Susan; Kantarjian Hagop; Keating Michael
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Thomas Deborah A; Sarris Andreas H; Cortes Jorge; Faderl Stefan; O'Brien Susan; Giles Francis J; Garcia-Manero Guillermo; Rodriguez Maria A; Cabanillas Fernando; Kantarjian Hagop
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Jabbour Elias; Kantarjian Hagop; O'Brien Susan; Rios Mary Beth; Abruzzo Lynne; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Blood 2006;107(2):480-2.
2005: Gandhi Varsha; Kilpatrick John M; Plunkett William; Ayres Mary; Harman Leigh; Du Min; Bantia Shanta; Davisson Jan; Wierda William G; Faderl Stefan; Kantarjian Hagop; Thomas Deborah
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Blood 2005;106(13):4253-60.
2005: Ravandi Farhad; O'Brien Susan; Jones Dan; Lerner Susan; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Garcia-Manero Guillermo; Thomas Deborah; Koller Charles; Verstovsek Srdan; Giles Francis; Cortes Jorge; Herling Marco; Kantarjian Hagop; Keating Michael
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Kantarjian Hagop
Trends in the management of chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3 Suppl 1():S41-5.
2005: Giles Francis; Verstovsek Srdan; Thomas Deborah; Gerson Stanton; Cortes Jorge; Faderl Stefan; Ferrajoli Alessandra; Ravandi Farhad; Kornblau Steven; Garcia-Manero Guillermo; Jabbour Elias; O'Brien Susan; Karsten Verena; Cahill Ann; Yee Karen; Albitar Maher; Sznol Mario; Kantarjian Hagop
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Merzianu Mihai; Medeiros L Jeffrey; Cortes Jorge; Yin Cameron; Lin Pei; Jones Dan; Glassman Armand; Kantarjian Hagop; Huh Yang
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
American journal of clinical pathology 2005;124(5):807-14.
2005: Ravandi Farhad; Kantarjian Hagop; Jones Dan; Dearden Claire; Keating Michael; O'Brien Susan
Mature T-cell leukemias.
Cancer 2005;104(9):1808-18.
2005: Cortes Jorge; Kantarjian Hagop
New targeted approaches in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6316-24.
2005: Talpaz Moshe; Rakhit Ashok; Rittweger Karen; O'Brien Susan; Cortes Jorge; Fettner Scott; Hooftman Leon; Kantarjian Hagop
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6247-55.
2005: Verstovsek Srdan; Golemovic Mirna; Kantarjian Hagop; Manshouri Tashi; Estrov Zeev; Manley Paul; Sun Tong; Arlinghaus Ralph B; Alland Leila; Dugan Margaret; Cortes Jorge; Giles Francis; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Canalli Andreia A; Yang Hui; Jeha Sima; Hoshino Koyu; Sanchez-Gonzalez Blanca; Brandt Mark; Pierce Sherry; Kantarjian Hagop; Issa Jean-Pierre; Garcia-Manero Guillermo
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
Leukemia research 2005;29(8):881-5.
2005: Jabbour Elias; Verstovsek Srdan; Giles Francis; Gandhi Varsha; Cortes Jorge; O'Brien Susan; Plunkett William; Garcia-Manero Guillermo; Jackson C Ellen; Kantarjian Hagop; Andreeff Michael
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Giles Francis; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Bueso-Ramos Carlos; Shan Jianqin; Pierce Sherry; Garcia-Manero Guillermo; Keating Michael; Kantarjian Hagop
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Golemovic Mirna; Verstovsek Srdan; Giles Francis; Cortes Jorge; Manshouri Taghi; Manley Paul W; Mestan Jürgen; Dugan Margaret; Alland Leila; Griffin James D; Arlinghaus Ralph B; Sun Tong; Kantarjian Hagop; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Yang Hui; Hoshino Koyu; Sanchez-Gonzalez Blanca; Kantarjian Hagop; Garcia-Manero Guillermo
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid.
Leukemia research 2005;29(7):739-48.
2005: Saba Rashid; Jabbour Elias; Giles Francis; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Freireich Emil J; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Bueso-Ramos Carlos; Xu Yunling; McDonnell Timothy J; Brisbay Shawn; Pierce Sherry; Kantarjian Hagop; Rosner Gary; Garcia-Manero Guillermo
Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3932-9.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Wierda William; O'Brien Susan; Wen Sijin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah; Do Kim-Anh; Cortes Jorge; Koller Charles; Beran Miloslav; Ferrajoli Alessandra; Giles Francis; Lerner Susan; Albitar Maher; Kantarjian Hagop; Keating Michael
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Issa Jean-Pierre; Kantarjian Hagop
Azacitidine.
Nature reviews. Drug discovery 2005;Suppl():S6-7.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Kontoyiannis Dimitrios P; Lionakis Michail S; Lewis Russell E; Chamilos Georgios; Healy Mimi; Perego Cheryl; Safdar Amar; Kantarjian Hagop; Champlin Richard; Walsh Thomas J; Raad Issam I
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
The Journal of infectious diseases 2005;191(8):1350-60.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Quintas-Cardama Alfonso; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Hayes Kimberly; Glassman Armand; Bekele B Nebiyou; Zhou Xian; Cortes Jorge
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Blood 2005;105(6):2281-6.
2005: Estey Elihu; Koller Charles; Tsimberidou Apostolia M; O'Brien Susan; Beran Miloslav; Cortes Jorge; Tirado-Gomez Maribel; Lopez-Berestein Gabriel; Kantarjian Hagop
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.
Blood 2005;105(3):1366-7.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Hennessy Bryan T; Thomas Deborah A; Giles Francis J; Kantarjian Hagop; Verstovsek Srdan
New approaches in the treatment of myelofibrosis.
Cancer 2005;103(1):32-43.
2004: Kantarjian Hagop; Thomas Deborah; O'Brien Susan; Cortes Jorge; Giles Francis; Jeha Sima; Bueso-Ramos Carlos E; Pierce Sherry; Shan Jianqin; Koller Charles; Beran Miloslav; Keating Michael; Freireich Emil J
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Konopleva Marina; Tsao Twee; Estrov Zeev; Lee Ruey-min; Wang Rui-Yu; Jackson C Ellen; McQueen Teresa; Monaco Giuseppe; Munsell Mark; Belmont John; Kantarjian Hagop; Sporn Michael B; Andreeff Michael
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.
Cancer research 2004;64(21):7927-35.
2004: Jabbour Elias; Kantarjian Hagop; Cortes Jorge
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Leukemia & lymphoma 2004;45(11):2187-95.
2004: Hennessy Bryan; Giles Francis; Cortes Jorge; O'brien Susan; Ferrajoli Alessandra; Ossa Gladys; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop; Verstovsek Srdan
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Cooper Todd; Kantarjian Hagop; Plunkett William; Gandhi Varsha
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Nucleosides, nucleotides & nucleic acids 2004;23(8-9):1417-23.
2004: Cortes Jorge; O'Brien Susan; Kantarjian Hagop
Discontinuation of imatinib therapy after achieving a molecular response.
Blood 2004;104(7):2204-5.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Hanna Hend; Benjamin Robert; Chatzinikolaou Ioannis; Alakech Badie; Richardson Deborah; Mansfield Paul; Dvorak Tanya; Munsell Mark F; Darouiche Rabih; Kantarjian Hagop; Raad Issam
Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3163-71.
2004: Odabasi Zekaver; Mattiuzzi Gloria; Estey Elihu; Kantarjian Hagop; Saeki Fumihiro; Ridge Richard J; Ketchum Paul A; Finkelman Malcolm A; Rex John H; Ostrosky-Zeichner Luis
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(2):199-205.
2004: Bueso-Ramos Carlos E; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Medeiros L Jeffrey; Kantarjian Hagop
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Garcia-Manero Guillermo; Rios Mary B; Talpaz Moshe; Cortes Jorge
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Cancer 2004;100(12):2592-7.
2004: Cortes Jorge; O'Brien Susan; Quintas Alfonso; Giles Francis; Shan Jianquin; Rios Mary Beth; Talpaz Moshe; Kantarjian Hagop
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Tsimberidou Apostolia-Maria; Medina Jorge; Cortes Jorge; Rios Adan; Bonnie Glisson; Faderl Stefan; Kantarjian Hagop; Garcia-Manero Guillermo
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Leukemia research 2004;28(6):657-60.
2004: Ault Patricia; Kantarjian Hagop; Welch Mary Alma; Giles Francis; Rios Mary Beth; Cortes Jorge
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Leukemia research 2004;28(6):613-8.
2004: Beran Miloslav; Luthra Rajyalakshmi; Kantarjian Hagop; Estey Elihu
FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.
Leukemia research 2004;28(6):547-50.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Cortes Jorge; Thomas Deborah; Koller Charles; Giles Francis; Estey Elihu; Faderl Stefan; Garcia-Manero Guillermo; McConkey David; Ruiz Stacey L; Guerciolini Roberto; Wright John; Kantarjian Hagop
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Cortes Jorge; Kantarjian Hagop
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cancer 2004;100(10):2064-78.
2004: Giles Francis; Thomas Deborah; Garcia-Manero Guillermo; Faderl Stefan; Cortes Jorge; Verstovsek Srdan; Ferrajoli Alessandra; Jeha Sima; Beran Miloslav; Koller Charles; Andreeff Michael; Cahill Ann; Clairmont Caroline; Sznol Mario; Kantarjian Hagop
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Smith B Douglas; Levis Mark; Beran Miloslav; Giles Francis; Kantarjian Hagop; Berg Karin; Murphy Kathleen M; Dauses Tianna; Allebach Jeffrey; Small Donald
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Blood 2004;103(10):3669-76.
2004: Tsao Anne S; Kantarjian Hagop; Thomas Deborah; Giles Francis; Cortes Jorge; Garcia-Manero Guillermo; Huh Yang; Yang Ying; Shen Yu; Albitar Maher; Estey Elihu
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
Leukemia research 2004;28(4):373-8.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: El-Zimaity Maha M T; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Thomas Deborah; Ferrajoli Alessandra; Hayes Kimberly; Nebiyou Bekele B; Zhou Xian; Rios Mary B; Glassman Armand B; Cortes Jorge E
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
British journal of haematology 2004;125(2):187-95.
2004: Giles Francis J; Kantarjian Hagop; Cortes Jorge
Novel therapies for patients with chronic myeloid leukemia.
Expert review of anticancer therapy 2004;4(2):271-82.
2004: Raad Issam; Hachem Ray; Hanna Hend; Afif Claude; Escalante Carmen; Kantarjian Hagop; Rolston Kenneth
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
The Journal of antimicrobial chemotherapy 2004;53(4):646-9.
2004: Rogers Anna; Joe Youngson; Manshouri Taghi; Dey Amanda; Jilani Iman; Giles Francis; Estey Elihu; Freireich Emil; Keating Michael; Kantarjian Hagop; Albitar Maher
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
Blood 2004;103(7):2799-801.
2004: Orsolic Nada; Giles Francis J; Gourdeau Henriette; Golemovic Mirna; Beran Miloslav; Cortes Jorge; Freireich Emil J; Kantarjian Hagop; Verstovsek Srdan
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
British journal of haematology 2004;124(6):727-38.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; Faderl Stefan; Lim JoAnn; Kontoyiannis Dimitrios; Thomas Deborah; Wierda William; Raad Isaam; Garcia-Manero Guillermo; Zhou Xian; Ferrajoli Alexandra; Bekele Nebiyou; Estey Elihu
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):581-9.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Ravandi Farhad; Kantarjian Hagop; Giles Francis; Cortes Jorge
New agents in acute myeloid leukemia and other myeloid disorders.
Cancer 2004;100(3):441-54.
2004: Jeha Sima; Gandhi Varsha; Chan Ka Wah; McDonald Lisa; Ramirez Irma; Madden Renee; Rytting Michael; Brandt Mark; Keating Michael; Plunkett William; Kantarjian Hagop
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
Blood 2004;103(3):784-9.
2004: Donato Nicholas J; Wu Ji Y; Stapley Jonathan; Lin Hui; Arlinghaus Ralph; Aggarwal Bharat B; Shishodia Shishir; Albitar Maher; Hayes Kimberly; Kantarjian Hagop; Talpaz Moshe;
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Cancer research 2004;64(2):672-7.
2004: Zangari Maurizio; Anaissie Elias; Stopeck Alison; Morimoto Alyssa; Tan Nguyen; Lancet Jeffrey; Cooper Maureen; Hannah Alison; Garcia-Manero Guillermo; Faderl Stephan; Kantarjian Hagop; Cherrington Julie; Albitar Maher; Giles Francis J
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2003: Gandhi Varsha; Kantarjian Hagop; Faderl Stefan; Bonate Peter; Du Min; Ayres Mary; Rios Mary Beth; Keating Michael J; Plunkett William
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6335-42.
2003: Tsao Anne S; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Talpaz Moshe
Imatinib mesylate causes hypopigmentation in the skin.
Cancer 2003;98(11):2483-7.
2003: Thomas Deborah A; Estey Elihu; Giles Francis J; Faderl Stefan; Cortes Jorge; Keating Michael; O'Brien Susan; Albitar Maher; Kantarjian Hagop
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
British journal of haematology 2003;123(3):436-41.
2003: Medina Jorge; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Rios Mary Beth; Hayes Kimberly; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Jilani Iman; O'Brien Susan; Manshuri Taghi; Thomas Deborah A; Thomazy Vilmos A; Imam Maha; Naeem Sana; Verstovsek Srdan; Kantarjian Hagop; Giles Francis; Keating Michael; Albitar Maher
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Blood 2003;102(10):3514-20.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorges; Shan Jianqin; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Rios Mary Beth; Talpaz Moshe
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Tsimberidou Apostolia; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stephan; Albitar Maher; Kantarjian Hagop; Estey Elihu; Giles Francis J
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Apostolidou Efrosyni; Cortes Jorge; Tsimberidou Apostolia; Estey Elihu; Kantarjian Hagop; Giles Francis J
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Leukemia research 2003;27(10):887-91.
2003: Kantarjian Hagop; Gandhi Varsha; Cortes Jorge; Verstovsek Srdan; Du Min; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; O'Brien Susan; Jeha Sima; Davis Jan; Shaked Zeev; Craig Adam; Keating Michael; Plunkett William; Freireich Emil J
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102(7):2379-86.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: Raad Issam I; Escalante Carmen; Hachem Ray Y; Hanna Hend A; Husni Rola; Afif Claude; Boktour Maha R; Whimbey Estella E; Kontoyiannis Dimitrios; Jacobson Kalen; Kantarjian Hagop; Levett L Martin; Rolston Kenneth V I
Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Cancer 2003;98(5):1039-47.
2003: Champlin Richard E; Kantarjian Hagop
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2003;1(7):398-400.
2003: Kontoyiannis Dimitrios P; Hachem Ray; Lewis Russell E; Rivero Gustavo A; Torres Harrys A; Thornby John; Champlin Richard; Kantarjian Hagop; Bodey Gerald P; Raad Issam I
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Cancer 2003;98(2):292-9.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Thomas Deborah; Kornblau Steven; Shan Jianquin; Beth Rios Mary; Keating Michael; Freireich Emil; Talpaz Moshe
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Verstovsek Srdan; Lunin Scott; Kantarjian Hagop; Manshouri Taghi; Faderl Stefan; Cortes Jorge; Giles Francis; Albitar Maher
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Estey Elihu; Giles Francis; Cortes Jorge; Beran Miloslav; Verstovsek Srdan; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Cortes Jorge; Ault Patricia; Koller Charles; Thomas Deborah; Ferrajoli Alessandra; Wierda William; Rios Mary B; Letvak Laurie; Kaled Elizabeth S; Kantarjian Hagop
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Blood 2003;101(12):4714-6.
2003: Duzkale Hatice; Jilani Iman; Orsolic Nada; Zingaro Ralph A; Golemovic Mirna; Giles Francis J; Kantarjian Hagop; Albitar Maher; Freireich Emil J; Verstovsek Srdan
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.
Cancer chemotherapy and pharmacology 2003;51(5):427-32.
2003: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; White Kevin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Kornblau Steven; Cortes Jorge
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Lazo Guillermo; Kantarjian Hagop; Estey Elihu; Thomas Deborah; O'Brien Susan; Cortes Jorge
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Cancer 2003;97(9):2218-24.
2003: Verstovsek Srdan; Manshouri Taghi; Smith Franklin O; Giles Francis J; Cortes Jorge; Estey Elihu; Kantarjian Hagop; Keating Michael; Jeha Sima; Albitar Maher
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Ibrahim Sherif; Jilani Iman; O'Brien Susan; Rogers Anna; Manshouri Taghi; Giles Francis; Faderl Stefan; Thomas Deborah; Kantarjian Hagop; Keating Michael; Albitar Maher
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Cancer 2003;97(8):1914-9.
2003: Apostolidou Efrosyni; Estey Elihu; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Tsimberidou Apostolia; Kantarjian Hagop; Giles Francis J
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Cools Jan; DeAngelo Daniel J; Gotlib Jason; Stover Elizabeth H; Legare Robert D; Cortes Jorges; Kutok Jeffrey; Clark Jennifer; Galinsky Ilene; Griffin James D; Cross Nicholas C P; Tefferi Ayalew; Malone James; Alam Rafeul; Schrier Stanley L; Schmid Janet; Rose Michal; Vandenberghe Peter; Verhoef Gregor; Boogaerts Marc; Wlodarska Iwona; Kantarjian Hagop; Marynen Peter; Coutre Steven E; Stone Richard; Gilliland D Gary
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
The New England journal of medicine 2003;348(13):1201-14.
2003: O'Brien Stephen G; Guilhot François; Larson Richard A; Gathmann Insa; Baccarani Michele; Cervantes Francisco; Cornelissen Jan J; Fischer Thomas; Hochhaus Andreas; Hughes Timothy; Lechner Klaus; Nielsen Johan L; Rousselot Philippe; Reiffers Josy; Saglio Giuseppe; Shepherd John; Simonsson Bengt; Gratwohl Alois; Goldman John M; Kantarjian Hagop; Taylor Kerry; Verhoef Gregor; Bolton Ann E; Capdeville Renaud; Druker Brian J;
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Faderl Stefan; Giles Francis J; Keating Michael; Albitar Maher
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: de Lima Marcos; Ravandi Farhad; Shahjahan Munir; Andersson Borje; Couriel Daniel; Donato Michele; Khouri Issa; Gajewski James; van Besien Koen; Champlin Richard; Giralt Sergio; Kantarjian Hagop
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
Cancer 2003;97(5):1242-7.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Cortes Jorge; Albitar Maher; Thomas Deborah; Giles Francis; Kurzrock Razelle; Thibault Alain; Rackoff Wayne; Koller Charles; O'Brien Susan; Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Wierda William G; Johnson Marcella M; Do Kim-Anh; Manshouri Taghi; Dey Amanda; O'Brien Susan; Giles Francis J; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Lerner Susan; Keating Michael; Albitar Maher
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2003: O'Brien Susan M; Kantarjian Hagop; Radich Jerald
Update: chronic myelogenous leukemia clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1 Suppl 1():S29-40.
2003: Cortes Jorge; Kantarjian Hagop
Advanced-phase chronic myeloid leukemia.
Seminars in hematology 2003;40(1):79-86.
2003: Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):114-9.
2003: Mattiuzzi Gloria N; Estey Elihu; Raad Issam; Giles Francis; Cortes Jorge; Shen Yu; Kontoyiannis Dimitrios; Koller Charles; Munsell Mark; Beran Miloslav; Kantarjian Hagop
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):450-6.
2003: Lu Di; Nounou Randa; Beran Miloslav; Estey Elihu; Manshouri Taghi; Kantarjian Hagop; Keating Michael J; Albitar Maher
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):441-9.
2003: Alvarado Yesid; Tsimberidou Apostolia; Kantarjian Hagop; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Estey Elihu; Giles Francis J
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2003: Alvarado Yesid; Cortes Jorge; Verstovsek Srdan; Thomas Deborah; Faderl Stephan; Estrov Zeev; Kantarjian Hagop; Giles Francis J
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2002: Guo J Q; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus R B
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(12):2447-53.
2002: Cortes Jorge; Tsimberidou Apostolia M; Alvarez Ricardo; Thomas Deborah; Beran Miloslav; Kantarjian Hagop; Estey Elihu; Giles Francis J
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2002;50(6):497-500.
2002: Huh Y O; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(11):2249-52.
2002: Kurzrock Razelle; Cortes Jorge; Kantarjian Hagop
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Seminars in hematology 2002;39(4 Suppl 3):20-4.
2002: Jilani Iman; Estey Elihu; Huh Yang; Joe Youngson; Manshouri Taghi; Yared Marwan; Giles Francis; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Keating Michael; Freireich Emil; Albitar Maher
Differences in CD33 intensity between various myeloid neoplasms.
American journal of clinical pathology 2002;118(4):560-6.
2002: Giles Francis; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Kantarjian Hagop; Estey Elihu
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Haematologica 2002;87(10):1114-6.
2002: Keating M J; O'Brien S; Kontoyiannis D; Plunkett W; Koller C; Beran M; Lerner S; Kantarjian H
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Lai Raymond; O'Brien Susan; Maushouri Taghi; Rogers Anna; Kantarjian Hagop; Keating Micheal; Albitar Maher
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
Cancer 2002;95(5):1071-5.
2002: Tsimberidou Apostolia-Maria; Thomas Deborah; O'Brien Susan; Andreeff Michael; Kurzrock Razelle; Keating Michael; Albitar Maher; Kantarjian Hagop; Giles Francis
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Cancer chemotherapy and pharmacology 2002;50(3):237-42.
2002: Ault Patricia; Cortes Jorge; Koller Charles; Kaled Elizabeth S; Kantarjian Hagop
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Leukemia research 2002;26(9):881-4.
2002: Verstovsek Srdan; Estey Elihu; Manshouri Taghi; Giles Francis J; Cortes Jorge; Beran Miloslav; Rogers Anna; Keating Michael; Kantarjian Hagop; Albitar Maher
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Atallah Ehab; Talpaz Moshe; O'brien Susan; Rios Mary Beth; Guo Jie Qiang; Arlinghaus Ralph; Fernandes-Reese Sofia; Kantarjian Hagop
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Cancer 2002;94(11):2996-9.
2002: Lin Chung Wu; Manshouri Taghi; Jilani Iman; Neuberg Donna; Patel Kunal; Kantarjian Hagop; Andreeff Michael; Estrov Zeev; Beran Miloslav; Keating Michael; Estey Elihu; Albitar Maher
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
Leukemia research 2002;26(6):551-9.
2002: Lee W I; Kantarjian H; Glassman A; Talpaz M; Lee M S
Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):781-8.
2002: Verstovsek Srdan; Lin Hui; Kantarjian Hagop; Saglio Giuseppe; De Micheli Daniela; Pane Fabrizio; Garcia-Manero Guillermo; Intrieri Mariano; Rotoli Bruno; Salvatore Francesco; Guo Jie Q; Talpaz Moshe; Specchia Giorgina; Pizzolo Gianni; Liberati Anna Marina; Cortes Jorge; Quackenbush Robert C; Arlinghaus Ralph B
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
Cancer 2002;94(9):2416-25.
2002: DiRaimondo Francesco; Albitar Maher; Huh Yang; O'Brien Susan; Montillo Marco; Tedeschi Alessandra; Kantarjian Hagop; Lerner Susan; Giustolisi Rosario; Keating Michael
The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease.
Cancer 2002;94(6):1721-30.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; O'Brien Susan; Faderl Stefan; Talpaz Moshe; Cortes Jorge; Albitar Maher
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2002: Cortes Jorge; Thomas Deborah; Rios Adan; Koller Charles; O'Brien Susan; Jeha Sima; Faderl Stefan; Kantarjian Hagop
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cancer 2002;94(5):1492-9.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Giles Francis J; Rogers Anna; Albitar Maher
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.
Blood 2002;99(6):2265-7.
2002: Surapaneni Usha R; Cortes Jorge E; Thomas Deborah; O'Brien Susan; Giles Francis J; Koller Charles; Faderl Stefan; Kantarjian Hagop
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Raad Issam; Hanna Hend; Osting Cheryl; Hachem Ray; Umphrey Jan; Tarrand Jeffrey; Kantarjian Hagop; Bodey Gerald P
Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2002;23(1):41-3.
2002: Ravandi Farhad; Talpaz Moshe; Kantarjian Hagop; Estrov Zeev
Cellular signalling pathways: new targets in leukaemia therapy.
British journal of haematology 2002;116(1):57-77.
2002: Lai Raymond; Estey Elihu; Shen Yu; Despa Simona; Kantarjian Hagop; Beran Miloslav; Maushouri Taghi; Quackenbuch Robert C; Keating Micheal; Albitar Maher
Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.
Cancer 2002;94(1):14-7.
2002: Faderl Stefan; Gandhi Varsha; Kantarjian Hagop; Plunkett William
New nucleoside analogues in clinical development.
Cancer chemotherapy and biological response modifiers 2002;20():37-58.
2002: Giles Francis; Garcia-Manero Guillermo; O'Brien Susan; Estey Eihu; Kantarjian Hagop
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Acta haematologica 2002;108(3):164-7.
2001: Cortes J; O'Brien S; Loscertales J; Kantarjian H; Giles F; Thomas D; Koller C; Keating M
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Cancer 2001;92(8):2016-22.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Soignet S L; Frankel S R; Douer D; Tallman M S; Kantarjian H; Calleja E; Stone R M; Kalaycio M; Scheinberg D A; Steinherz P; Sievers E L; Coutré S; Dahlberg S; Ellison R; Warrell R P
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3852-60.
2001: Cheson B D; Bennett J M; Kantarjian H; Schiffer C A; Nimer S D; Löwenberg B; Stone R M; Mittelman M; Sanz G F; Wijermans P W; Greenberg P L
Myelodysplastic syndromes standardized response criteria: further definition.
Blood 2001;98(6):1985.
2001: Verstovsek S; Kantarjian H; Aguayo A; Manshouri T; Freireich E; Keating M; Estey E; Albitar M
Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
British journal of haematology 2001;114(2):290-5.
2001: Kalidas M; Kantarjian H; Talpaz M
Chronic myelogenous leukemia.
JAMA : the journal of the American Medical Association 2001;286(8):895-8.
2001: Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles F J; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(8):1165-70.
2001: Verstovsek S; Estey E; Manshouri T; Keating M; Kantarjian H; Giles F J; Albitar M
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia & lymphoma 2001;42(3):511-6.
2001: Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Leukemia & lymphoma 2001;42(3):309-16.
2001: Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Ravandi F; Kantarjian H; Cohen A; Davis M; O'Brien S; Anderlini P; Andersson B; Claxton D; Donato M; Gajewski J; Khouri I; Korbling M; Ueno N; deVos D; Champlin R; Giralt S
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Bone marrow transplantation 2001;27(12):1221-5.
2001: Kurzrock R; Bueso-Ramos C E; Kantarjian H; Freireich E; Tucker S L; Siciliano M; Pilat S; Talpaz M
BCR rearrangement-negative chronic myelogenous leukemia revisited.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2915-26.
2001: Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating M J
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):621-5.
2001: Donato N J; Wu J Y; Zhang L; Kantarjian H; Talpaz M
Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Blood 2001;97(9):2846-53.
2001: O'Brien S M; Kantarjian H; Thomas D A; Giles F J; Freireich E J; Cortes J; Lerner S; Keating M J
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: Druker B J; Sawyers C L; Kantarjian H; Resta D J; Reese S F; Ford J M; Capdeville R; Talpaz M
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
2001: Druker B J; Talpaz M; Resta D J; Peng B; Buchdunger E; Ford J M; Lydon N B; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers C L
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
2001: Aguayo A; Manshouri T; O'Brien S; Keating M; Beran M; Koller C; Kantarjian H; Rogers A; Albitar M
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).
Leukemia research 2001;25(4):279-85.
2001: Tannir N M; Kantarjian H
Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia.
Leukemia & lymphoma 2001;41(1-2):217-20.
2001: Laurent E; Talpaz M; Kantarjian H; Kurzrock R
The BCR gene and philadelphia chromosome-positive leukemogenesis.
Cancer research 2001;61(6):2343-55.
2001: Pachmann K; Zhao S; Schenk T; Kantarjian H; El-Naggar A K; Siciliano M J; Guo J Q; Arlinghaus R B; Andreeff M
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
British journal of haematology 2001;112(3):749-59.
2001: Nguyen Q; Estey E; Raad I; Rolston K; Kantarjian H; Jacobson K; Konoplev S; Ghosh S; Luna M; Tarrand J; Whimbey E
Cytomegalovirus pneumonia in adults with leukemia: an emerging problem.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32(4):539-45.
2001: Sarriera J E; Albitar M; Estrov Z; Gidel C; Aboul-Nasr R; Manshouri T; Kornblau S; Chang K S; Kantarjian H; Estey E
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(1):57-61.
2001: Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Investigational new drugs 2001;19(1):13-20.
2000: Rodriguez J; McLaughlin P; Fayad L; Santiago M; Hess M; Rodriguez M A; Romaguera J; Hagemeister F; Kantarjian H; Cabanillas F
Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1551-6.
2000: Cheson B D; Bennett J M; Kantarjian H; Pinto A; Schiffer C A; Nimer S D; Löwenberg B; Beran M; de Witte T M; Stone R M; Mittelman M; Sanz G F; Wijermans P W; Gore S; Greenberg P L;
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
Blood 2000;96(12):3671-4.
2000: Berman E; Clift R A; Copelan E A; Emanuel P D; Erba H P; Glenn M J; Greenberg P L; Jones R J; O'Brien S; Saba H I; Schilder R; Snyder D S; Soiffer R J; Tallman M S; Wetzler M; Ravandi-Kashani F; Kantarjian H; Talpaz M;
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
Oncology (Williston Park, N.Y.) 2000;14(11A):229-40.
2000: Kozuch P; Talpaz M; Faderl S; O'Brien S; Freireich E J; Kantarjian H
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?
Cancer 2000;89(7):1482-9.
2000: Talpaz M; Qiu X; Cheng K; Cortes J E; Kantarjian H; Kurzrock R
Autoantibodies to Abl and Bcr proteins.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(9):1661-6.
2000: Aguayo A; Kantarjian H; Manshouri T; Gidel C; Estey E; Thomas D; Koller C; Estrov Z; O'Brien S; Keating M; Freireich E; Albitar M
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Blood 2000;96(6):2240-5.
2000: Aguayo A; O'Brien S; Keating M; Manshouri T; Gidel C; Barlogie B; Beran M; Koller C; Kantarjian H; Albitar M
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Blood 2000;96(2):768-70.
2000: Ravandi-Kashani F; O'Brien S; Manshouri T; Lerner S; Sim S; Dodd K; Kantarjian H; Freireich E; Keating M; Albitar M
Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia.
Leukemia research 2000;24(6):469-74.
2000: Seong C M; Giralt S; Kantarjian H; Xu J; Swantkowski J; Hayes K; Glassman A B; Khouri I; Korbling M; Thall P; Siciliano M J; Champlin R E
Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1831-6.
2000: Kornblau S M; Vu H T; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May W S
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1401-9.
2000: Keating M J; Smith T L; Lerner S; O'Brien S; Robertson L E; Kantarjian H; Freireich E J
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):71-85.
2000: Chung C Y; Kantarjian H; Haidar M; Starostik P; Manshouri T; Gidel C; Freireich E; Keating M; Albitar M
Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance.
Cancer 2000;88(6):1359-64.
2000: Haidar M A; Kantarjian H; Manshouri T; Chang C Y; O'Brien S; Freireich E; Keating M; Albitar M
ATM gene deletion in patients with adult acute lymphoblastic leukemia.
Cancer 2000;88(5):1057-62.
2000: Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: Vey N; Giles F J; Kantarjian H; Smith T L; Beran M; Jeha S
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):731-6.
2000: Keyhani A; Huh Y O; Jendiroba D; Pagliaro L; Cortez J; Pierce S; Pearlman M; Estey E; Kantarjian H; Freireich E J
Increased CD38 expression is associated with favorable prognosis in adult acute leukemia.
Leukemia research 2000;24(2):153-9.
2000: Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles F J; Pierce S; Albitar M
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Sarris A H; Hagemeister F; Romaguera J; Rodriguez M A; McLaughlin P; Tsimberidou A M; Medeiros L J; Samuels B; Pate O; Oholendt M; Kantarjian H; Burge C; Cabanillas F
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):69-72.
2000: Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith T L; Rios M B; Kantarjian H
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):147-52.
2000: Faber J; Kantarjian H; Roberts M W; Keating M; Freireich E; Albitar M
Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia.
Archives of pathology & laboratory medicine 2000;124(1):92-7.
1999: Partyka S; O'Brien S; Podoloff D; Kantarjian H; Keating M J
The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation.
Leukemia & lymphoma 1999;36(1-2):151-5.
1999: Lin C W; O'Brien S; Faber J; Manshouri T; Romaguera J; Huh Y O; Kantarjian H; Keating M; Albitar M
De novo CD5+ Burkitt lymphoma/leukemia.
American journal of clinical pathology 1999;112(6):828-35.
1999: Aguayo A; Estey E; Kantarjian H; Mansouri T; Gidel C; Keating M; Giles F; Estrov Z; Barlogie B; Albitar M
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 1999;94(11):3717-21.
1999: Khouri I F; Lee M S; Romaguera J; Mirza N; Kantarjian H; Korbling M; Albitar M; Giralt S; Samuels B; Anderlini P; Rodriguez J; von Wolff B; Gajewski J; Cabanillas F; Champlin R
Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1293-9.
1999: Kantarjian H
New developments in the treatment of acute myeloid leukemia: focus on topotecan.
Seminars in hematology 1999;36(4 Suppl 8):16-25.
1999: Beran M; Kantarjian H
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Seminars in hematology 1999;36(4 Suppl 8):3-10.
1999: Thomas D A; Kantarjian H; Smith T L; Koller C; Cortes J; O'Brien S; Giles F J; Gajewski J; Pierce S; Keating M J
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Cancer 1999;86(7):1203-9.
1999: Estey E H; Giles F J; Kantarjian H; O'Brien S; Cortes J; Freireich E J; Lopez-Berestein G; Keating M
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Beran M; Estey E; O'Brien S; Cortes J; Koller C A; Giles F J; Kornblau S; Andreeff M; Vey N; Pierce S R; Hayes K; Wong G C; Keating M; Kantarjian H
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Leukemia & lymphoma 1999;35(1-2):109-18.
1999: Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2491-7.
1999: Starostik P; O'Brien S; Chung C Y; Haidar M; Manshouri T; Kantarjian H; Freireich E; Keating M; Albitar M
The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia.
Leukemia research 1999;23(9):795-801.
1999: Thomas D A; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister F B; Cabanillas F F; Murphy S; Keating M J; Kantarjian H
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2461-70.
1999: Kornblau S M; Thall P F; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating M J; Kantarjian H; Estey E; Andreeff M
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1758-66.
1999: O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios M B; Talpaz M
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
Blood 1999;93(12):4149-53.
1999: Patmasiriwat P; Fraizer G; Kantarjian H; Saunders G F
WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):891-900.
1999: Estey E H; Thall P F; Reed P; Kantarjian H; Beran M; Pierce S; Keating M J
Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):850-4.
1999: Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):577-83.
1999: Estey E H; Thall P F; Pierce S; Cortes J; Beran M; Kantarjian H; Keating M J; Andreeff M; Freireich E
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Blood 1999;93(8):2478-84.
1999: Albitar M; Manshouri T; Kantarjian H; Keating M; Estrov Z; Faber J; Freireich E J; Pierce S; Estey E
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.
Leukemia research 1999;23(1):63-9.
1999: Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Investigational new drugs 1999;17(1):89-95.
1999: Cortes J; O'Brien S; Estey E; Giles F; Keating M; Kantarjian H
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1998: Jeha S; Kantarjian H; O'Brien S; Vitek L; Beran M
Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia.
Leukemia & lymphoma 1998;32(1-2):159-64.
1998: Khouri I F; Romaguera J; Kantarjian H; Palmer J L; Pugh W C; Korbling M; Hagemeister F; Samuels B; Rodriguez A; Giralt S; Younes A; Przepiorka D; Claxton D; Cabanillas F; Champlin R
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3803-9.
1998: Rodriguez J; Cortes J; Smith T; O'Brien S; Rios M B; Talpaz M; Kantarjian H
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3782-7.
1998: Starostik P; Manshouri T; O'Brien S; Freireich E; Kantarjian H; Haidar M; Lerner S; Keating M; Albitar M
Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.
Cancer research 1998;58(20):4552-7.
1998: Cortes J; Talpaz M; O'Brien S; Rios M B; Majlis A; Keating M; Freireich E J; Kantarjian H
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3279-85.
1998: Anaissie E J; Kontoyiannis D P; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating M J
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Annals of internal medicine 1998;129(7):559-66.
1998: Kornblau S M; Andreeff M; Hu S X; Xu H J; Patel S; Theriault A; Koller C; Kantarjian H; Estey E; Deisseroth A B; Benedict W F
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1955-63.
1998: Jendiroba D B; Lichtiger B; Anaissie E; Reddy V; O'Brien S; Kantarjian H; Freireich E J
Evaluation and comparison of three mobilization methods for the collection of granulocytes.
Transfusion 1998;38(8):722-8.
1998: Keating M J; O'Brien S; Lerner S; Koller C; Beran M; Robertson L E; Freireich E J; Estey E; Kantarjian H
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood 1998;92(4):1165-71.
1998: Beran M; Kantarjian H
Topotecan in the treatment of hematologic malignancies.
Seminars in hematology 1998;35(3 Suppl 4):26-31.
1998: Kantarjian H
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Seminars in hematology 1998;35(3 Suppl 4):1-2.
1998: Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus R B; Lydon N B; Kantarjian H
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1661-72.
1998: Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson L E; O'Brien S
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2321-31.
1998: Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(6):860-4.
1998: Cortes J; Fayad L; Kantarjian H; O'Brien S; Lee M S; Talpaz M
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(4):455-62.
1998: Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1526-31.
1998: DeLima M; Albitar M; O'Brien S; Pierce S; Kantarjian H; Andreeff M; Fayad L; Keating M; Estey E
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
The American journal of medicine 1998;104(3):246-51.
1998: Kornblau S M; Kantarjian H; O'Brien S; Andreeff M; Koller C A; Beran M; Keating M; Estey E
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Leukemia & lymphoma 1998;28(3-4):371-5.
1998: Munker R; Kantarjian H; O'Brien S; Keating M; Andreeff M; Estey E H
Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule.
Acta haematologica 1998;99(2):106-8.
1997: Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo M G; Rios M B; Keating M; Kantarjian H
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2377-84.
1997: de Lima M; Strom S S; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E; Estey E
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
Blood 1997;90(12):4719-24.
1997: Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
Blood 1997;90(8):2969-77.
1997: Estey E; Thall P; Kantarjian H; Pierce S; Kornblau S; Keating M
Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1661-4.
1997: O'Brien S; Kantarjian H; Beran M; Koller C; Talpaz M; Lerner S; Keating M J
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1631-5.
1997: Dignani M C; Anaissie E J; Hester J P; O'Brien S; Vartivarian S E; Rex J H; Kantarjian H; Jendiroba D B; Lichtiger B; Andersson B S; Freireich E J
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1621-30.
1997: Cortes J; Kantarjian H; O'Brien S; Beran M; Estey E; Keating M; Talpaz M
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):929-32.
1997: Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Blood 1997;89(12):4531-6.
1997: Cortes J; Kantarjian H; Talpaz M; O'Brien S; Beran M; Koller C; Keating M
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(6):788-91.
1997: Kornblau S M; Estey E; Madden T; Tran H T; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman R A; Andreeff M
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1796-802.
1997: Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
Studies of decitabine with allogeneic progenitor cell transplantation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 1():S32-4.
1997: Gisslinger H; Kurzrock R; Wetzler M; Tucker S; Kantarjian H; Robertson B; Talpaz M
Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences.
Leukemia & lymphoma 1997;25(1-2):121-33.
1997: Estey E; Thall P F; Pierce S; Kantarjian H; Keating M
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):483-90.
1997: Sacchi S; Cortes J; Kantarjian H; Talpaz M
Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
Hematopathology and molecular hematology 1997;11(1):41-7.
1996: Keating M J; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: O'Brien S; Kantarjian H; Talpaz M
Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha.
Leukemia & lymphoma 1996;23(3-4):247-52.
1996: Guo J Q; Lian J; Glassman A; Talpaz M; Kantarjian H; Deisseroth A B; Arlinghaus R B
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
American journal of clinical pathology 1996;106(4):442-8.
1996: Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese J L; Andreeff M; Keating M; Estey E
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 1996;88(7):2473-9.
1996: Patmasiriwat P; Fraizer G C; Claxton D; Kantarjian H; Saunders G F
Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(7):1127-33.
1996: Cortes J E; Talpaz M; Kantarjian H
Chronic myelogenous leukemia: a review.
The American journal of medicine 1996;100(5):555-70.
1996: Cortes J; Kantarjian H; O'Brien S; Robertson L E; Pierce S; Talpaz M
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
The American journal of medicine 1996;100(4):452-5.
1996: Sarris A; Cortes J; Kantarjian H; Pierce S; Smith T; Keating M; Koller C; Kornblau S; O'Brien S; Andreeff M
Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.
Leukemia & lymphoma 1996;21(1-2):85-92.
1996: Jeha S; Luo X N; Beran M; Kantarjian H; Atweh G F
Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells.
Cancer research 1996;56(6):1445-50.
1996: O'Brien S; Jeha S; Kantarjian H; Pisa P; Jin G; Keating M; Beran M
Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(2):338-44.
1996: Anaissie E J; Vartivarian S; Bodey G P; Legrand C; Kantarjian H; Abi-Said D; Karl C; Vadhan-Raj S
Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia.
The American journal of medicine 1996;100(1):17-23.
1996: O'Brien S; Kantarjian H; Keating M J
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 6():S27-33.
1995: Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Blood 1995;86(11):4337-43.
1995: Jeha S; Kantarjian H; O'Brien S; Huh Y; Pisa P; Ordonez N; Beran M
Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency.
Blood 1995;86(11):4278-85.
1995: O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson L E; Hester J; Rios M B; Andreeff M; Talpaz M
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
Blood 1995;86(9):3322-6.
1995: Sacchi S; Kantarjian H; O'Brien S; Cohen P R; Pierce S; Talpaz M
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2401-7.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating M J
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1444-9.
1995: Giralt S; Kantarjian H; Talpaz M
Treatment of chronic myelogenous leukemia.
Seminars in oncology 1995;22(4):396-404.
1995: O'Brien S; Kantarjian H; Beran M; Robertson L E; Koller C; Lerner S; Keating M J
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Blood 1995;86(4):1298-300.
1995: Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Blood 1995;85(11):3257-63.
1995: Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E J; Estey E
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):965-71.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating M J
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):943-5.
1995: Giralt S; Kantarjian H; Talpaz M
The natural history of chronic myelogenous leukemia in the interferon era.
Seminars in hematology 1995;32(2):152-8.
1995: O'Brien S; Kantarjian H; Ellis A; Zwelling L; Estey E; Keating M
Topotecan in chronic lymphocytic leukemia.
Cancer 1995;75(5):1104-8.
1995: Cortes J E; Kantarjian H; O'Brien S; Keating M; Pierce S; Freireich E J; Estey E
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(1):115-7.
1994: Dimopoulos M A; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2694-8.
1994: Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich E J; Keating M; Pierce S; Estey E
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2174-8.
1994: Robertson L E; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating M J
Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2047-51.
1994: Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Leukemia & lymphoma 1994;16(1-2):79-88.
1994: Wetzler M; Kurzrock R; Estrov Z; Kantarjian H; Gisslinger H; Underbrink M P; Talpaz M
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
Blood 1994;84(9):3142-7.
1994: Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
The Journal of clinical investigation 1994;94(4):1383-9.
1994: O'Brien S; Kurzrock R; Duvic M; Kantarjian H; Stass S; Robertson L E; Estey E; Pierce S; Keating M J
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Blood 1994;84(3):733-8.
1994: Giralt S; O'Brien S; Weeks E; Luna M; Kantarjian H
Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid.
Leukemia & lymphoma 1994;14(5-6):453-6.
1994: Cortes J E; Kantarjian H; O'Brien S; Robertson L E; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
Cancer 1994;73(12):2946-52.
1994: Bodey G P; Anaissie E J; Elting L S; Estey E; O'Brien S; Kantarjian H
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Cancer 1994;73(8):2099-106.
1994: Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson L E; Koller C; Kornblau S
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):671-8.
1994: Dimopoulos M A; Weber D M; Kantarjian H; Keating M; Alexanian R
2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):288-9.
1994: O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
The New England journal of medicine 1994;330(5):319-22.
1994: Keating M J; O'Brien S; Plunkett W; Robertson L E; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1994: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Li Y Y; Gandhi V
The expanding role of fludarabine in hematologic malignancies.
Leukemia & lymphoma 1994;14 Suppl 2():11-6.
1994: Keating M J; Estey E; O'Brien S; Kantarjian H; Robertson L E; Plunkett W
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1993: Estey E H; Kantarjian H; Keating M
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Seminars in oncology 1993;20(6 Suppl 8):1-5.
1993: Robertson L E; Pugh W; O'Brien S; Kantarjian H; Hirsch-Ginsberg C; Cork A; McLaughlin P; Cabanillas F; Keating M J
Richter's syndrome: a report on 39 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1985-9.
1993: Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios M B; Plunkett W; Keating M
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Cancer 1993;72(7):2155-60.
1993: Gutiérrez de Guzmán J; Kantarjian H
[Role of retinoic acid in the treatment of acute promyelocytic leukemia]
Sangre 1993;38(5):375-8.
1993: Deisseroth A B; Kantarjian H; Talpaz M; Champlin R; Reading C; Hanania E G; Fu S; Randhawa G S; Cha Y; Fang X
Molecular approaches to the diagnosis and treatment of cancer.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():129-30.
1993: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang L Y; Gandhi V
New initiatives with fludarabine monophosphate in hematologic malignancies.
Seminars in oncology 1993;20(5 Suppl 7):13-20.
1993: O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson L E; Lerner S; Keating M
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Blood 1993;82(6):1695-700.
1993: Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich E J; Andersson B S; O'Brien S; Andreeff M; Fisher H; Cork A
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
The New England journal of medicine 1993;329(11):757-61.
1993: Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson B S; Kohli V; Kantarjian H
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Cancer research 1993;53(15):3603-10.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating M J
Fludarabine therapy in Waldenström's macroglobulinemia.
The American journal of medicine 1993;95(1):49-52.
1993: Keating M J; O'Brien S; Kantarjian H; Plunkett W; Estey E; Koller C; Beran M; Freireich E J
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: Kemena A; O'Brien S; Kantarjian H; Robertson L; Koller C; Beran M; Estey E; Plunkett W; Lerner S; Keating M J
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Estey E; Plunkett W; Gandhi V; Rios M B; Kantarjian H; Keating M J
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leukemia & lymphoma 1993;9(4-5):343-50.
1993: Deisseroth A B; Kantarjian H; Talpaz M; Champlin R; Reading C; Andersson B; Claxton D
Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.
Human gene therapy 1993;4(1):71-85.
1993: Dimopoulos M A; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating M J; Freireich E J; Alexanian R
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman J U; Talpaz M
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Experimental hematology 1993;21(1):80-5.
1993: Estey E H; Plunkett W; Kantarjian H; Rios M B; Keating M J
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Keating M J; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Chronic lymphocytic leukemia--correlation of response and survival.
Leukemia & lymphoma 1993;11 Suppl 2():167-75.
1993: Keating M J; O'Brien S; Kantarjian H; Robertson L B; Koller C; Beran M; Estey E
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;10 Suppl():139-45.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Estey E E; Keating M J; Alexanian R
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Leukemia & lymphoma 1993;11 Suppl 2():105-8.
1993: Estey E; Pierce S; Kantarjian H; O'Brien S; Beran M; Andreeff M; Escudier S; Koller C; Kornblau S; Robertson L
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Leukemia & lymphoma 1993;11 Suppl 2():59-63.
1992: Lee M; Khouri I; Champlin R; Kantarjian H; Talpaz M; Trujillo J; Freireich E; Deisseroth A; Stass S
Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.
British journal of haematology 1992;82(4):708-14.
1992: Seong D C; Gottlieb K; Suh S P; Sims S; Talpaz M; Kantarjian H; Deisseroth A
Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals.
Journal of interferon research 1992;12(5):323-7.
1992: Anaissie E; Kontoyiannis D P; Kantarjian H; Elting L; Robertson L E; Keating M
Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.
Annals of internal medicine 1992;117(6):466-9.
1992: Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman P S; Ku S; Gutterman J U; Talpaz M
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(8):754-60.
1992: O'Brien S; Kantarjian H; Freireich E; Johnston D; Nguyen K; Beran M
CI-973, a new platinum derivative with potential antileukemic activity.
Cancer research 1992;52(15):4130-4.
1992: Robertson L E; Huh Y O; Butler J J; Pugh W C; Hirsch-Ginsberg C; Stass S; Kantarjian H; Keating M J
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Blood 1992;80(1):29-36.
1992: Estey E; Thall P F; Kantarjian H; O'Brien S; Koller C A; Beran M; Gutterman J; Deisseroth A; Keating M
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Blood 1992;79(9):2246-55.
1992: Lee M S; Kantarjian H; Talpaz M; Freireich E J; Deisseroth A; Trujillo J M; Stass S A
Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
Blood 1992;79(8):1920-3.
1992: Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):406-13.
1992: Talpaz M; Chernajovsky Y; Troutman-Worden K; Wetzler M; Kantarjian H; Gutterman J U; Kurzrock R
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.
Cancer research 1992;52(5):1087-90.
1992: Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
Blood 1992;79(4):997-1002.
1992: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
Cancer 1992;69(2):410-2.
1992: Estey E; Trujillo J M; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich E J; Stass S
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
Hematologic pathology 1992;6(1):43-8.
1992: Keating M J; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich E J
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():78-80.
1992: Yuan T; Zhou Y Q; Herst C V; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
Progress in clinical and biological research 1992;377():227-30.
1991: Wetzler M; Kurzrock R; Lowe D G; Kantarjian H; Gutterman J U; Talpaz M
Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.
Blood 1991;78(9):2400-6.
1991: Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman J U
A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Cancer 1991;68(10):2125-30.
1991: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Interferon alpha in the therapy of CML.
British journal of haematology 1991;79 Suppl 1():38-41.
1991: Schilling P J; Kurzrock R; Kantarjian H; Gutterman J U; Talpaz M
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
Cancer 1991;68(7):1536-7.
1991: Estrov Z; Kurzrock R; Wetzler M; Kantarjian H; Blake M; Harris D; Gutterman J U; Talpaz M
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
Blood 1991;78(6):1476-84.
1991: Anaissie E; Bodey G P; Kantarjian H; David C; Barnett K; Bow E; Defelice R; Downs N; File T; Karam G
Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.
The American journal of medicine 1991;91(2):142-50.
1991: O'Brien S; Kantarjian H; Estey E; Koller C; Beran M; McCredie K; Keating M
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
Cancer 1991;68(4):691-4.
1991: Seong D; Sims S; Johnson E; Lyding J; Lopez A; Garovoy M; Talpaz M; Kantarjian H; Lopez-Berestein G; Reading C
Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.
British journal of haematology 1991;78(3):359-67.
1991: O'Brien S; Witt R; Talpaz M; Kantarjian H
Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
Cancer 1991;67(7):1946-9.
1991: Talpaz M; Kantarjian H; Kurzrock R; Trujillo J M; Gutterman J U
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Annals of internal medicine 1991;114(7):532-8.
1991: Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman J U; Kurzrock R
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(3):191-5.
1991: Keating M J; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs C C; Freireich E J; McCredie K B
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):44-9.
1990: Wedrychowski A; Seong D; Paslidis N; Johnson E; Howard O M; Sims S; Talpaz M; Kantarjian H; Hester J; Turpin J
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells.
The Journal of biological chemistry 1990;265(35):21433-40.
1990: Seong D C; Sims S; Johnson E; Howard O M; Reiter B; Hester J; Talpaz M; Kantarjian H; Deisseroth A
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes.
The Journal of clinical investigation 1990;86(5):1664-70.
1990: Grunewald R; Kantarjian H; Keating M J; Abbruzzese J; Tarassoff P; Plunkett W
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Cancer research 1990;50(21):6823-6.
1990: Howard O M; Talpaz M; Kantarjian H; Seong D; Wedrychowski A; Paslidis N; Hester J; Cork A; Turpin J; Lopez-Berestein G
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
Blood 1990;76(6):1117-30.
1990: Hirsch-Ginsberg C; LeMaistre A C; Kantarjian H; Talpaz M; Cork A; Freireich E J; Trujillo J M; Lee M S; Stass S A
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
Blood 1990;76(6):1214-9.
1990: Wetzler M; Kurzrock R; Taylor K; Spitzer G; Kantarjian H; Baiocchi G; Ku S; Gutterman J U; Talpaz M
Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma.
Cancer research 1990;50(18):5801-5.
1990: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Update on therapeutic options for chronic myelogenous leukemia.
Seminars in hematology 1990;27(3 Suppl 4):31-6.
1990: Bodey G P; Fainstein V; Elting L S; Anaissie E; Rolston K; Khardori N; Kantarjian H; Plager C; Murphy W K; Holmes F
Beta-lactam regimens for the febrile neutropenic patient.
Cancer 1990;65(1):9-16.
1990: Mashal R; Shtalrid M; Talpaz M; Kantarjian H; Smith L; Beran M; Cork A; Trujillo J; Gutterman J; Deisseroth A
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.
Blood 1990;75(1):180-9.
1990: Seong D; Sims S S; Johnson E; Swan F; Lyding J; Lopez A; Talpaz M; Kantarjian H; Emerson S; Lopez-Berestein G
Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia.
Transactions of the Association of American Physicians 1990;103():236-41.
1990: Claxton D; Kantarjian H; Kurzrock R; Trujillo J M; Gutterman J U; Talpaz M
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
Acta haematologica 1990;83(3):149-51.
1989: Keating M J; Kantarjian H; Smith T L; Estey E; Walters R; Andersson B; Beran M; McCredie K B; Freireich E J
Response to salvage therapy and survival after relapse in acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1071-80.
1989: Keating M J; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich E J; McCredie K B
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman J U
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
The American journal of medicine 1989;86(5):554-8.
1989: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
Bone marrow transplantation 1989;4 Suppl 1():63.
1989: Talpaz M; Kurzrock R; Kantarjian H; Gutterman J
Therapy of chronic myelogenous leukaemia with interferons.
Cancer surveys 1989;8(4):793-8.
1989: Kurzrock R; Gutterman J U; Kantarjian H; Talpaz M
Therapy of chronic myelogenous leukemia with interferon.
Cancer investigation 1989;7(1):83-91.
1988: Hittelman W N; Agbor P; Petkovic I; Andersson B; Kantarjian H; Walters R; Koller C; Beran M
Detection of leukemic clone maturation in vivo by premature chromosome condensation.
Blood 1988;72(6):1950-60.
1988: Schachner J; Kantarjian H; Dalton W; McCredie K; Keating M; Freireich E J
Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(10):667-71.
1988: Shtalrid M; Talpaz M; Blick M; Romero P; Kantarjian H; Taylor K; Trujillo J; Schachner J; Gutterman J U; Kurzrock R
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1569-75.
1988: Shtalrid M; Talpaz M; Kurzrock R; Kantarjian H; Trujillo J; Gutterman J; Yoffe G; Blick M
Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia.
Blood 1988;72(2):485-90.
1988: Keating M J; Smith T L; Kantarjian H; Cork A; Walters R; Trujillo J M; McCredie K B; Gehan E A; Freireich E J
Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(7):403-12.
1988: Anaissie E J; Fainstein V; Bodey G P; Rolston K; Elting L; Kantarjian H; Cabanillas F; McCredie K B
Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients.
The American journal of medicine 1988;84(3 Pt 2):581-9.
1988: Amato R; Kantarjian H; Walters R; Keating M
Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia.
Cancer 1988;61(4):650-3.
1988: O'Brien S; Kantarjian H; Shtalrid M; Blick M; Beran M; Talpaz M
Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Hematologic pathology 1988;2(1):25-9.
1988: Keating M J; Kantarjian H; Talpaz M; Redman J; McCredie K B
Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Nouvelle revue française d'hématologie 1988;30(5-6):461-6.
1987: Kantarjian H; Walters R
Implications of cytogenetic findings in secondary leukemia.
American journal of clinical oncology 1987;10(5):453-6.
1987: Kurzrock R; Talpaz M; Kantarjian H; Walters R; Saks S; Trujillo J M; Gutterman J U
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
Blood 1987;70(4):943-7.
1987: Talpaz M; Kantarjian H; McCredie K; Trujillo J; Keating M; Gutterman J U
Therapy of chronic myelogenous leukemia.
Cancer 1987;59(3 Suppl):664-7.
1987: Beran M; Andersson B; Kantarjian H; Keating M; Rios A; McCredie K B; Freireich E J; Gutterman J
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(1):52-7.
1986: Talpaz M; McCredie K; Kantarjian H; Trujillo J; Keating M; Gutterman J
Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
British journal of haematology 1986;64(1):87-95.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Hagop Kantarjian

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Hagop Kantarjian (preview)

All Publications